


**CUMULATIVE  
SUPPLEMENT 2  
FEBRUARY 2023**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**43rd EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

2023

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**43<sup>rd</sup> EDITION**

**Cumulative Supplement 2  
February 2023**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**43<sup>rd</sup> EDITION**

**CUMULATIVE SUPPLEMENT 2  
FEBRUARY 2023**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)

ALEOR DERMACEUTICALS LTD  
(ALEOR DERMACEUTICALS)

ALEMBIC PHARMACEUTICALS LTD  
(ALEMBIC PHARMS)

EMCURE PHARMACEUTICALS LTD  
(EMCURE PHARMS)

AVET LIFESCIENCES LTD  
(AVET LIFESCIENCES)

EMCURE PHARMACEUTICALS LTD  
(EMCURE PHARMS LTD)

AVET LIFESCIENCES LTD  
(AVET LIFESCIENCES)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
---------	------------------	-----------	----------	---------	-----	----

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).



Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

## REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2022</u>	<u>MAR</u> <u>2023</u>	<u>JUN</u> <u>2023</u>	<u>SEP</u> <u>2023</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	21983 2718 (12.4%)				
MULTISOURCE	19265 (87.6%)				
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)				
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)				
EXCEPTIONS <sup>4</sup>	46 (0.2%)				
NEW MOLECULAR ENTITIES APPROVED	8				
NUMBER OF APPLICANTS	1211				

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL  
 ABIRATERONE ACETATE  
 AB TEVA PHARMS USA 500MG A210726 001 Jan 26, 2023 Jan NEWA

ACARBOSE

TABLET;ORAL  
 ACARBOSE  
 >A> @ DASH PHARMS 25MG A091053 001 Jan 06, 2011 Feb CAHN  
 >A> @ 50MG A091053 002 Jan 06, 2011 Feb CAHN  
 >A> @ 100MG A091053 003 Jan 06, 2011 Feb CAHN  
 >D> @ MYLAN 25MG A091053 001 Jan 06, 2011 Feb CAHN  
 >D> @ 50MG A091053 002 Jan 06, 2011 Feb CAHN  
 >D> @ 100MG A091053 003 Jan 06, 2011 Feb CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL  
 BUTALBITAL AND ACETAMINOPHEN  
 AA SENORES PHARMS 300MG;50MG A214088 001 Apr 07, 2022 Jan CAHN  
 AA 325MG;25MG A214088 002 Apr 07, 2022 Jan CAHN  
 AA 325MG;50MG A214088 003 Apr 07, 2022 Jan CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL  
 ACETAZOLAMIDE  
 >D> @ INDICUS PHARMA 500MG A090779 001 Jul 14, 2011 Feb CMFD  
 >A> AB 500MG A090779 001 Jul 14, 2011 Feb CMFD  
 TABLET;ORAL  
 ACETAZOLAMIDE  
 @ BRECKENRIDGE 125MG A207503 001 Apr 30, 2020 Jan DISC  
 @ 250MG A207503 002 Apr 30, 2020 Jan DISC

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC  
 ACETIC ACID  
 @ CHARTWELL RX 2% A040166 001 Jul 26, 1996 Jan CAHN

ACYCLOVIR

CREAM;TOPICAL  
 ACYCLOVIR  
 >A> AB ZYDUS LIFESCIENCES 5% A206770 001 Feb 28, 2023 Feb NEWA

ALBUTEROL SULFATE

TABLET;ORAL  
 ALBUTEROL SULFATE  
 >A> AB DASH PHARMS NATCO EQ 2MG BASE A072894 002 Jan 17, 1991 Feb CAHN  
 >A> AB ! EQ 4MG BASE A072894 001 Jan 17, 1991 Feb CAHN  
 >D> AB MYLAN EQ 2MG BASE A072894 002 Jan 17, 1991 Feb CAHN  
 >D> AB ! EQ 4MG BASE A072894 001 Jan 17, 1991 Feb CAHN

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED;INHALATION  
 AIRSUPRA  
 >A> +! ASTRAZENECA EQ 90MCG BASE/INH;80MCG/INH N214070 001 Jan 10, 2023 Feb CAHN  
 >D> +! BOND EQ 90MCG BASE/INH;80MCG/INH N214070 001 Jan 10, 2023 Feb CAHN  
 +! EQ 90MCG BASE/INH;80MCG/INH N214070 001 Jan 10, 2023 Jan NEWA

ALVIMOPAN

CAPSULE;ORAL  
 ALVIMOPAN  
 AB PAR PHARM 12MG A216843 001 Jan 24, 2023 Jan NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL  
 AMANTADINE HYDROCHLORIDE  
 >D> BX STRIDES PHARMA 100MG A209047 001 Jun 07, 2017 Feb CTEC  
 >A> AB 100MG A209047 001 Jun 07, 2017 Feb CTEC

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

>D>	BX	STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Feb CTEC
>A>	AB		100MG	A209035	001	Jun 09, 2017	Feb CTEC

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>D>	AP	FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015	Feb DISC
>A>		@	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015	Feb DISC
>D>	AP	! HIKMA	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Feb CTEC
>A>		!	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Feb CTEC

AMINO ACIDS

INJECTABLE; INJECTION

FREAMINE HBC 6.9%

@ B BRAUN

6.9% (6.9GM/100ML)

N016822 006 May 17, 1983 Jan DISC

FREAMINE III 10%

@ B BRAUN

10% (10GM/100ML)

N016822 005 Jan DISC

FREAMINE III 8.5%

@ B BRAUN

8.5% (8.5GM/100ML)

N016822 004 Jan DISC

HEPATAMINE 8%

@ B BRAUN

8% (8GM/100ML)

N018676 001 Aug 03, 1982 Jan DISC

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE

@ B BRAUN

3%;26MG/100ML;3GM/100ML;54MG/100ML  
;41MG/100ML;150MG/100ML;200MG/100ML;  
L;120MG/100ML

N018582 001 May 08, 1982 Jan DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

@ B BRAUN

8.5%;110MG/100ML;230MG/100ML;10MG/  
100ML;440MG/100ML;690MG/100ML

N016822 007 Jul 01, 1988 Jan DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES

@ B BRAUN

3%;54MG/100ML;40MG/100ML;150MG/100  
ML;200MG/100ML;120MG/100ML

N016822 003 Jan DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>D>	AB	APOTEX	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb CAHN
>D>	AB		EQ 5MG BASE	A076719	002	May 23, 2007	Feb CAHN
>D>	AB		EQ 10MG BASE	A076719	003	May 23, 2007	Feb CAHN
>A>	AB	COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb CAHN
>A>	AB		EQ 5MG BASE	A076719	002	May 23, 2007	Feb CAHN
>A>	AB		EQ 10MG BASE	A076719	003	May 23, 2007	Feb CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>D>	AP	WISCONSIN	3.75mCi-260mCi/ML	A204356	001	Dec 18, 2014	Feb DISC
>A>		@	3.75mCi-260mCi/ML	A204356	001	Dec 18, 2014	Feb DISC

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ CHARTWELL RX

125MG/5ML

A062059 001 Jan CAHN

@

250MG/5ML

A062059 002 Jan CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

>D>	DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
>D>	AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
>D>	AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Feb CTNA
>D>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
>D>	AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
	AB		1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan NEWA
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan NEWA
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan NEWA
>D>	AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Feb CTNA
	AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan NEWA
>D>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
	AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan NEWA
>D>		@ LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
>D>		@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
>D>		@	3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CMFD
>D>		@	5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CMFD
>D>		@	6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CMFD
>D>		@	7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CMFD
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
>D>		@ ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
>A>	AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
>A>	AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Feb CTNA
>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
>A>	AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
>A>	AB		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Feb CTNA
>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan NEWA
>A>	AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CMFD
>A>	AB		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Feb CMFD
>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Feb CMFD
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Feb CMFD

TABLET;ORAL

	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
>D>		@ LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Feb CMFD
>A>	AB		1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Feb CMFD
>D>		@	1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Feb CMFD
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Feb CMFD
>D>		@	2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Feb CMFD
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Feb CMFD
>D>		@	3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Feb CMFD
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Feb CMFD
>D>		@	3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Feb CMFD
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Feb CMFD
>D>		@	5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Feb CMFD
>A>	AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Feb CMFD
>D>		@	7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Feb CMFD
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Feb CMFD

AMPICILLIN SODIUM

INJECTABLE;INJECTION  
AMPICILLIN SODIUM

	@	STERISCIENCE	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Jan CAHN
	@		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Jan CAHN
AP			EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Jan CAHN
AP			EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Jan CAHN
AP			EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTION  
AMPICILLIN AND SULBACTAM

AP	STERISCIENCE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Jan	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Jan	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Jan	CAHN

APALUTAMIDETABLET; ORAL  
ERLEADA

>D>	+!	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb	CHRS
>A>	+		60MG	N210951	001	Feb 14, 2018	Feb	CHRS
>A>	+!		240MG	N210951	002	Feb 17, 2023	Feb	NEWA

APIXABANTABLET; ORAL  
APIXABAN

>A>	AB	ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023	Feb	NEWA
>A>	AB		5MG	A210185	002	Feb 27, 2023	Feb	NEWA

APREMILASTTABLET; ORAL  
APREMILAST

>D>	AB	TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb	DISC
>A>		@	10MG	A211897	001	Aug 18, 2022	Feb	DISC
>D>	AB		20MG	A211897	002	Aug 18, 2022	Feb	DISC
>A>		@	20MG	A211897	002	Aug 18, 2022	Feb	DISC
>D>	AB		30MG	A211897	003	Aug 18, 2022	Feb	DISC
>A>		@	30MG	A211897	003	Aug 18, 2022	Feb	DISC

ARFORMOTEROL TARTRATESOLUTION; INHALATION  
ARFORMOTEROL TARTRATE

>D>		@ RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb	CMFD
>A>	AN		EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb	CMFD

ARMODAFINILTABLET; ORAL  
ARMODAFINIL

>D>		@ APOTEX	50MG	A201514	001	Mar 25, 2019	Feb	CAHN
>D>		@	150MG	A201514	002	Mar 25, 2019	Feb	CAHN
>D>		@	250MG	A201514	003	Mar 25, 2019	Feb	CAHN
>A>		@ COREPHARMA	50MG	A201514	001	Mar 25, 2019	Feb	CAHN
>A>		@	150MG	A201514	002	Mar 25, 2019	Feb	CAHN
>A>		@	250MG	A201514	003	Mar 25, 2019	Feb	CAHN

ATORVASTATIN CALCIUMSUSPENSION; ORAL  
ATORVALIQ

>A>		+!	CMP DEV LLC	20MG/5ML	N213260	001	Feb 01, 2023	Feb	NEWA
-----	--	----	-------------	----------	---------	-----	--------------	-----	------

AZELAIC ACIDAEROSOL, FOAM; TOPICAL  
FINACEA

>D>	AB	+!	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015	Feb	CTEC
>A>		+!		15%	N207071	001	Jul 29, 2015	Feb	CTEC

AZELASTINE HYDROCHLORIDESPRAY, METERED; NASAL  
AZELASTINE HYDROCHLORIDE

>D>	AB		PADAGIS ISRAEL	0.2055MG/SPRAY	A202743	001	May 08, 2014	Feb	DISC
>A>		@		0.2055MG/SPRAY	A202743	001	May 08, 2014	Feb	DISC

AZITHROMYCINTABLET; ORAL  
AZITHROMYCIN

		@ ACI	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jan	DISC
		@	EQ 500MG BASE	A215773	001	Jul 12, 2022	Jan	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

@ AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A 065213	001	Jul 25, 2012	Jan DISC
! BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A 064068	001	Oct 30, 1995	Jan CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A 065088	001	Feb 06, 2004	Jan DISC
---------	--	----------	-----	--------------	----------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

>A> AP	RUBICON	0.5MG/ML	A 217324	001	Feb 22, 2023	Feb NEWA
>A> AP		1MG/ML	A 217324	002	Feb 22, 2023	Feb NEWA
>A> AP		2MG/ML	A 217324	003	Feb 22, 2023	Feb NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>A>	@ DASH PHARMS NATCO	750MG	A 077807	001	Dec 28, 2007	Feb CAHN
>D>	@ MYLAN	750MG	A 077807	001	Dec 28, 2007	Feb CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

>A> AP	BRECKENRIDGE	25MG/VIAL	A 205447	001	Feb 14, 2023	Feb NEWA
>A> AP		100MG/VIAL	A 205447	002	Feb 14, 2023	Feb NEWA

SOLUTION;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

+ @ HOSPIRA	25MG/ML (25MG/ML)	N 211530	001	Dec 15, 2022	Jan DISC
+ @	100MG/4ML (25MG/ML)	N 211530	002	Dec 15, 2022	Jan DISC
+ @	200MG/8ML (25MG/ML)	N 211530	003	Dec 15, 2022	Jan DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

>D> AA	ALEMBIC LABS	100MG	A 040682	001	Jul 30, 2007	Feb CAHN
>D> AA		200MG	A 040682	002	Jul 30, 2007	Feb CAHN
>A> AA	CHARTWELL RX	100MG	A 040682	001	Jul 30, 2007	Feb CAHN
>A> AA		200MG	A 040682	002	Jul 30, 2007	Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

>D>						
>D> AB	+! BAUSCH	5%;EQ 1% BASE	N 050756	001	Dec 21, 2000	Feb DISC
>A>	+ @	5%;EQ 1% BASE	N 050756	001	Dec 21, 2000	Feb DISC
>D> AB	GLENMARK PHARMS	5%;EQ 1% BASE	A 209252	001	Mar 14, 2019	Feb CHRS
>A> AB	!	5%;EQ 1% BASE	A 209252	001	Mar 14, 2019	Feb CHRS

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB	HIKMA	3MG/ML;EQ 3MG BASE/ML	A 077838	001	Jan 17, 2023	Jan NEWA
----	-------	-----------------------	----------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>D> AB	TOLMAR	0.064%;0.005%	A 201615	001	Jan 14, 2013	Feb DISC
>A>	@	0.064%;0.005%	A 201615	001	Jan 14, 2013	Feb DISC

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>A> AB	COSETTE	0.064%;0.005%	A 210765	001	May 11, 2020	Feb CAHN
>D> AB	TOLMAR	0.064%;0.005%	A 210765	001	May 11, 2020	Feb CAHN



BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
BETAXOLOL HYDROCHLORIDE

>D> AT AKORN EQ 0.5% BASE A075386 001 Jun 30, 2000 Feb DISC  
>A> @ EQ 0.5% BASE A075386 001 Jun 30, 2000 Feb DISC

BEXAGLIFLOZIN

TABLET;ORAL  
BRENZAVVY

+! THERACOSBIO 20MG N214373 001 Jan 20, 2023 Jan NEWA

BICALUTAMIDE

TABLET;ORAL  
BICALUTAMIDE

AB PINNACLE LIFE SCI 50MG A079089 001 Jul 06, 2009 Jan CAHN

BIMATOPROST

IMPLANT;OPHTHALMIC  
DURYSTA

+! ABBVIE 10MCG N211911 001 Mar 04, 2020 Jan CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

>A> BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE  
>A> AB PAR PHARM 140MG;125MG;125MG A205770 001 Mar 06, 2023 Feb NFTG  
PYLERA  
>D> +! ALLERGAN 140MG;125MG;125MG N050786 001 Sep 28, 2006 Feb CFTG  
>A> AB +! 140MG;125MG;125MG N050786 001 Sep 28, 2006 Feb CFTG

BISOPROLOL FUMARATE

TABLET;ORAL  
BISOPROLOL FUMARATE

>A> AB ALEMBIC 5MG A204891 001 Jan 11, 2017 Feb CAHN  
>A> AB 10MG A204891 002 Jan 11, 2017 Feb CAHN  
>D> AB ALEMBIC LABS 5MG A204891 001 Jan 11, 2017 Feb CAHN  
>D> AB 10MG A204891 002 Jan 11, 2017 Feb CAHN  
>A> @ DASH PHARMS NATCO 5MG A075831 001 Dec 14, 2005 Feb CAHN  
>A> @ 10MG A075831 002 Dec 14, 2005 Feb CAHN  
>D> @ MYLAN 5MG A075831 001 Dec 14, 2005 Feb CAHN  
>D> @ 10MG A075831 002 Dec 14, 2005 Feb CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS  
BORTEZOMIB

>D> AP ACCORD HLTHCARE 3.5MG/VIAL A204405 001 Jul 26, 2022 Feb DISC  
>A> @ 3.5MG/VIAL A204405 001 Jul 26, 2022 Feb DISC  
SOLUTION;INTRAVENOUS  
BORTEZOMIB  
>D> +! ACCORD HLTHCARE 2.5MG/ML (2.5MG/ML) N215441 001 Jul 26, 2022 Feb DISC  
>A> + @ 2.5MG/ML (2.5MG/ML) N215441 001 Jul 26, 2022 Feb DISC  
>D> +! 3.5MG/1.4ML (2.5MG/ML) N215441 002 Jul 26, 2022 Feb DISC  
>A> + @ 3.5MG/1.4ML (2.5MG/ML) N215441 002 Jul 26, 2022 Feb DISC

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION  
BRETYLIUM TOSYLATE

>D> ! BRECKENRIDGE 50MG/ML A204386 001 Dec 21, 2018 Feb DISC  
>A> @ 50MG/ML A204386 001 Dec 21, 2018 Feb DISC

BREXPIPIRAZOLE

TABLET;ORAL  
BREXPIPIRAZOLE

AB AJANTA PHARMA LTD 0.25MG A213718 001 Feb 03, 2023 Jan NEWA  
AB 0.5MG A213718 002 Feb 03, 2023 Jan NEWA  
AB 1MG A213718 003 Feb 03, 2023 Jan NEWA  
AB 2MG A213718 004 Feb 03, 2023 Jan NEWA  
AB 3MG A213718 005 Feb 03, 2023 Jan NEWA  
AB 4MG A213718 006 Feb 03, 2023 Jan NEWA  
>D> AB TEVA PHARMS USA INC 0.25MG A213692 001 Aug 11, 2022 Feb DISC  
>A> @ 0.25MG A213692 001 Aug 11, 2022 Feb DISC  
>D> AB 0.5MG A213692 002 Aug 11, 2022 Feb DISC

TABLET;ORAL

BREXPIPIRAZOLE

>A>	@	0.5MG	A213692	002	Aug 11, 2022	Feb	DISC
>D>	AB	1MG	A213692	003	Aug 11, 2022	Feb	DISC
>A>	@	1MG	A213692	003	Aug 11, 2022	Feb	DISC
>D>	AB	2MG	A213692	004	Aug 11, 2022	Feb	DISC
>A>	@	2MG	A213692	004	Aug 11, 2022	Feb	DISC
>D>	AB	3MG	A213692	005	Aug 11, 2022	Feb	DISC
>A>	@	3MG	A213692	005	Aug 11, 2022	Feb	DISC
>D>	AB	4MG	A213692	006	Aug 11, 2022	Feb	DISC
>A>	@	4MG	A213692	006	Aug 11, 2022	Feb	DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@	BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jan	DISC
---	--------------	---------------------------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>D>	@	FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Feb	CAHN
>D>	@		10MG	A075413	002	Mar 19, 2002	Feb	CAHN
>D>	@		15MG	A075413	003	Mar 19, 2002	Feb	CAHN
>A>	@	GRAVITI PHARMS	5MG	A075413	001	Mar 19, 2002	Feb	CAHN
>A>	@		10MG	A075413	002	Mar 19, 2002	Feb	CAHN
>A>	@		15MG	A075413	003	Mar 19, 2002	Feb	CAHN

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

@	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Jan	DISC
---	-----------	--------	---------	-----	--------------	-----	------

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

>D>	+	@	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb	CMFD
>A>		+		60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb	CMFD
>A>	AP		APOTEX	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Feb	NEWA
>A>	AP		DR REDDYS	60MG/1.5ML (40MG/ML)	A207718	001	Feb 10, 2023	Feb	NEWA
		+	SANDOZ INC	45MG/4.5ML (10MG/ML)	N208715	001	Jan 05, 2023	Jan	NEWA
		+		60MG/6ML (10MG/ML)	N208715	002	Jan 05, 2023	Jan	NEWA

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

>D>	AB		TOLMAR	0.005%	A200935	001	May 30, 2012	Feb	DISC
>A>		@		0.005%	A200935	001	May 30, 2012	Feb	DISC

SOLUTION;TOPICAL

CALCIPOTRIENE

>D>	AT		COSETTE	0.005%	A078468	001	Mar 24, 2011	Feb	CHRS
>A>	AT	!		0.005%	A078468	001	Mar 24, 2011	Feb	CHRS
>D>	AT	!	TOLMAR	0.005%	A077029	001	Nov 20, 2009	Feb	DISC
>A>		@		0.005%	A077029	001	Nov 20, 2009	Feb	DISC

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB			CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023	Jan	NEWA
AB				25MG	A214442	002	Jan 27, 2023	Jan	NEWA
AB				50MG	A214442	003	Jan 27, 2023	Jan	NEWA
AB				100MG	A214442	004	Jan 27, 2023	Jan	NEWA

CARBAMAZEPINE

SUSPENSION;ORAL

CARBAMAZEPINE

AB			CHARTWELL RX	100MG/5ML	A075714	001	Jun 05, 2002	Jan	CAHN
----	--	--	--------------	-----------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

>A>	AB		SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb	NEWA
>A>	AB			200MG	A216235	002	Mar 02, 2023	Feb	NEWA
>A>	AB			400MG	A216235	003	Mar 02, 2023	Feb	NEWA

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION  
CARBOPROST TROMETHAMINE

>A> AP CAPLIN EQ 0.25MG BASE/ML A216882 001 Feb 13, 2023 Feb NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL  
VRAYLAR

+! ABBVIE EQ 1.5MG BASE N204370 001 Sep 17, 2015 Jan CAHN  
+ EQ 3MG BASE N204370 002 Sep 17, 2015 Jan CAHN  
+ EQ 4.5MG BASE N204370 003 Sep 17, 2015 Jan CAHN  
+ EQ 6MG BASE N204370 004 Sep 17, 2015 Jan CAHN

CARMUSTINE

INJECTABLE; INJECTION  
CARMUSTINE

>A> AP MYLAN LABS LTD 100MG/VIAL A215368 001 Mar 03, 2023 Feb NEWA

CELECOXIB

SOLUTION; ORAL  
ELYXYB

>D> + @ BDSI 25MG/ML N212157 001 May 05, 2020 Feb CAHN  
>A> + @ SCILEX HLDG 25MG/ML N212157 001 May 05, 2020 Feb CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL  
CHLORHEXIDINE GLUCONATE

AT CHARTWELL RX 0.12% A075006 001 Mar 03, 2004 Jan CAHN

CHLORZOXAZONE

TABLET; ORAL  
CHLORZOXAZONE

AB APPCO 375MG A212047 001 Jan 27, 2023 Jan NEWA  
AB 750MG A212047 002 Jan 27, 2023 Jan NEWA  
AA BELCHER 250MG A215540 001 Jan 24, 2023 Jan NEWA

CICLOPIROX

SOLUTION; TOPICAL  
CICLOPIROX

AT ! PADAGIS US 8% A077623 001 Sep 18, 2007 Jan CHRS  
+ @ VALEANT BERMUDA 8% N021022 001 Dec 17, 1999 Jan DISC

CIPROFLOXACIN

INJECTABLE, SUSPENSION; OTIC  
OTIPRIO

+ @ ALK ABELLO 6% (60MG/ML) N207986 001 Dec 10, 2015 Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
CIPROFLOXACIN HYDROCHLORIDE

>D> AT AKORN EQ 0.3% BASE A076555 001 Dec 11, 2008 Feb DISC  
>A> @ EQ 0.3% BASE A076555 001 Dec 11, 2008 Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL  
CELEXA

>A> AB + ABBVIE EQ 10MG BASE N020822 001 Apr 27, 2000 Feb CAHN  
>A> AB + EQ 20MG BASE N020822 002 Jul 17, 1998 Feb CAHN  
>A> AB +! EQ 40MG BASE N020822 003 Jul 17, 1998 Feb CAHN  
>A> @ EQ 60MG BASE N020822 004 Jul 17, 1998 Feb CAHN  
>D> AB + ALLERGAN EQ 10MG BASE N020822 001 Apr 27, 2000 Feb CAHN  
>D> AB + EQ 20MG BASE N020822 002 Jul 17, 1998 Feb CAHN  
>D> AB +! EQ 40MG BASE N020822 003 Jul 17, 1998 Feb CAHN  
>D> @ EQ 60MG BASE N020822 004 Jul 17, 1998 Feb CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D>	AA	ALEMBIC LABS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Feb CAHN
>A>	AA	CHARTWELL RX	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Feb CAHN

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ XTTRIUM LABS INC EQ 1% BASE

A063304 001 Jul 15, 1997 Jan CAHN

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

>D>	AB1	TORRENT	0.05%	A211836	001	Dec 30, 2019	Feb DISC
>A>		@	0.05%	A211836	001	Dec 30, 2019	Feb DISC

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB		AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998	Jan CMFD
AB			1MG	A075150	002	Oct 05, 1998	Jan CMFD
AB			2MG	A075150	003	Oct 05, 1998	Jan CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

>A>		@ DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987	Feb CAHN
>A>		@	7.5MG	A071510	001	Oct 19, 1987	Feb CAHN
>A>		@	15MG	A071511	001	Oct 19, 1987	Feb CAHN
>D>		@ MYLAN	3.75MG	A071509	001	Oct 19, 1987	Feb CAHN
>D>		@	7.5MG	A071510	001	Oct 19, 1987	Feb CAHN
>D>		@	15MG	A071511	001	Oct 19, 1987	Feb CAHN

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB		IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	Jan NEWA
----	--	-------	---------------	---------	-----	--------------	----------

CROMOLYN SODIUM

SOLUTION/DROPS;OPHTHALMIC

CROMOLYN SODIUM

>D>	AT	! AKORN	4%	A074706	001	Apr 29, 1998	Feb DISC
>A>		@	4%	A074706	001	Apr 29, 1998	Feb DISC
>D>	AT	SANDOZ INC	4%	A075282	001	Jun 16, 1999	Feb CTEC
>A>		!	4%	A075282	001	Jun 16, 1999	Feb CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB	ALEMBIC LABS	5MG	A078218	002	Jun 19, 2015	Feb CAHN
>D>	AB		7.5MG	A078218	003	Nov 03, 2020	Feb CAHN
>D>	AB		10MG	A078218	001	Apr 18, 2008	Feb CAHN
>A>	AB	CHARTWELL RX	5MG	A078218	002	Jun 19, 2015	Feb CAHN
>A>	AB		7.5MG	A078218	003	Nov 03, 2020	Feb CAHN
>A>	AB		10MG	A078218	001	Apr 18, 2008	Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOGYL

>D>	AT	+! ALCON LABS INC	0.5%	A084109	001		Feb CTEC
>A>		+!	0.5%	A084109	001		Feb CTEC
>D>	AT	AKORN	0.5%	A205937	001	Dec 09, 2015	Feb DISC
>A>		@	0.5%	A205937	001	Dec 09, 2015	Feb DISC

CYCLOSPORINE

	EMULSION;OPHTHALMIC							
	CYCLOSPORINE							
AB	APOTEX	0.05%		A207606	001	Jan 12, 2023	Jan	NEWA
	SOLUTION;ORAL							
	CYCLOSPORINE							
AB2	XTTRIUM LABS INC	100MG/ML		A065133	001	Sep 17, 2004	Jan	CAHN

CYSTEINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	CYSTEINE HYDROCHLORIDE							
	NIVAGEN PHARMS INC	7.25%		A213073	001	Jan 26, 2023	Jan	NFTG

>A> DAPRODUSTAT

>A>	TABLET;ORAL							
>A>	JESDUVROQ							
>A>	+ GLAXOSMITHKLINE	1MG		N216951	001	Feb 01, 2023	Feb	NEWA
>A>	+	2MG		N216951	002	Feb 01, 2023	Feb	NEWA
>A>	+	4MG		N216951	003	Feb 01, 2023	Feb	NEWA
>A>	+	6MG		N216951	004	Feb 01, 2023	Feb	NEWA
>A>	+	8MG		N216951	005	Feb 01, 2023	Feb	NEWA

DAPTOMYCIN

	POWDER; INTRAVENOUS							
	DAPTOMYCIN							
>D> AP	HAINAN POLY PHARM	500MG/VIAL		A215890	001	Aug 18, 2022	Feb	DISC
>A>	@	500MG/VIAL		A215890	001	Aug 18, 2022	Feb	DISC
	+! XELLIA PHARMS APS	350MG/VIAL		N217415	001	Jan 30, 2023	Jan	NEWA
	+!	500MG/VIAL		N217415	002	Jan 30, 2023	Jan	NEWA

DESLORATADINE

	TABLET;ORAL							
	DESLORATADINE							
>A>	@ DASH PHARMS	5MG		A078351	001	Feb 10, 2012	Feb	CAHN
>D>	@ MYLAN PHARMS INC	5MG		A078351	001	Feb 10, 2012	Feb	CAHN

DEUTETRABENAZINE

>A>	TABLET, EXTENDED RELEASE;ORAL							
>A>	AUSTEDO XR							
>A>	+ TEVA	6MG		N216354	001	Feb 17, 2023	Feb	NEWA
>A>	+	12MG		N216354	002	Feb 17, 2023	Feb	NEWA
>A>	+!	24MG		N216354	003	Feb 17, 2023	Feb	NEWA

DEXAMETHASONE

	ELIXIR;ORAL							
	DEXAMETHASONE							
	+ @ XTTRIUM LABS INC	0.5MG/5ML		A088254	001	Jul 27, 1983	Jan	CAHN
	TABLET;ORAL							
	DEXAMETHASONE							
>D> AB	PRASCO	4MG		A080399	002	Apr 20, 2022	Feb	DISC
>A>	@	4MG		A080399	002	Apr 20, 2022	Feb	DISC

DEXTROAMPHETAMINE SULFATE

	TABLET;ORAL							
	DEXTROAMPHETAMINE SULFATE							
AA	ARBOR PHARMS LLC	2.5MG		A090533	001	Oct 25, 2011	Jan	CTEC
AA		7.5MG		A090533	003	Oct 25, 2011	Jan	CTEC
AA		15MG		A090533	005	Oct 25, 2011	Jan	CTEC
AA		20MG		A090533	006	Oct 25, 2011	Jan	CTEC
AA		30MG		A090533	007	Oct 25, 2011	Jan	CTEC
AA	WINDER LABS LLC	2.5MG		A212160	001	Jun 07, 2021	Jan	CMFD
AA		5MG		A212160	002	Jun 07, 2021	Jan	CMFD
AA		7.5MG		A212160	003	Jun 07, 2021	Jan	CMFD
AA		10MG		A212160	004	Jun 07, 2021	Jan	CMFD
AA		15MG		A212160	005	Jun 07, 2021	Jan	CMFD
AA		20MG		A212160	006	Jun 07, 2021	Jan	CMFD
AA		30MG		A212160	007	Jun 07, 2021	Jan	CMFD

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

>A>	AB	AMNEAL	3%	A200936	001	Oct 28, 2013	Feb CAHN
>D>	AB	TOLMAR	3%	A200936	001	Oct 28, 2013	Feb CAHN

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB	AUROLIFE PHARMA LLC	2%	A213040	001	Feb 03, 2023	Jan NEWA
----	---------------------	----	---------	-----	--------------	----------

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

BENTYL

>A>	AP	+! ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Feb CAHN
>D>	AP	+! ALLERGAN	10MG/ML	N008370	001	Oct 15, 1984	Feb CAHN

BENTYL PRESERVATIVE FREE

>A>	AP	+! ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Feb CAHN
>D>	AP	+! ALLERGAN	10MG/ML	N008370	002	Oct 15, 1984	Feb CAHN

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

>D>	@ AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Feb CMFD
>A>	AB	20MG	A040317	001	Sep 07, 1999	Feb CMFD

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

>D>	AB	! LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Feb CTEC
>A>		!	75MG	A091680	001	Oct 24, 2011	Feb CTEC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB1	TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb NEWA
>A>	AB1		90MG	A217377	002	Mar 01, 2023	Feb NEWA
>A>	AB1		120MG	A217377	003	Mar 01, 2023	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB	AMTA	120MG	A216439	001	Mar 07, 2023	Feb NEWA
>A>	AB		180MG	A216439	002	Mar 07, 2023	Feb NEWA
>A>	AB		240MG	A216439	003	Mar 07, 2023	Feb NEWA
>A>	AB		300MG	A216439	004	Mar 07, 2023	Feb NEWA
>A>	AB		360MG	A216439	005	Mar 07, 2023	Feb NEWA
>A>	AB		420MG	A216439	006	Mar 07, 2023	Feb NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

>D>	@ SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Feb CMFD
>A>	AB	120MG	A210436	001	Mar 26, 2021	Feb CMFD
>D>	@	240MG	A210436	002	Mar 26, 2021	Feb CMFD
>A>	AB	240MG	A210436	002	Mar 26, 2021	Feb CMFD

DISULFIRAM

TABLET;ORAL

DISULFIRAM

>A>	@ DASH PHARMS	250MG	A203916	001	Mar 04, 2015	Feb CAHN
>A>	@	500MG	A203916	002	Mar 04, 2015	Feb CAHN
>D>	@ MYLAN	250MG	A203916	001	Mar 04, 2015	Feb CAHN
>D>	@	500MG	A203916	002	Mar 04, 2015	Feb CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

>A>	AP	ALEMNIC	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb NEWA
>A>	AP		80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb NEWA
>A>	AP		160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb NEWA

DOXEPIN HYDROCHLORIDE

CREAM;TOPICAL

>A>		DOXEPIN HYDROCHLORIDE						
>A>	AB	TEVA PHARMS	5%	A215408	001	Feb 17, 2023	Feb	NFTG
		ZONALON						
>D>	+	MYLAN	5%	N020126	001	Apr 01, 1994	Feb	CFTG
>A>	AB	+	5%	N020126	001	Apr 01, 1994	Feb	CFTG

DOXYCYCLINE HYCLATE

TABLET;ORAL

DOXYCYCLINE HYCLATE

>D>		@ AMICI	EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb	CAHN
>A>		@ ORYZA PHARMS SHENZHN	EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb	CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

+	@	SUN PHARM	EQ 40MG BASE	N212516	003	Jul 19, 2019	Jan	DISC
---	---	-----------	--------------	---------	-----	--------------	-----	------

ELACESTRANT DIHYDROCHLORIDE

TABLET;ORAL

ORSERDU

+		STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Jan	NEWA
+	!		EQ 345MG BASE	N217639	002	Jan 27, 2023	Jan	NEWA

EMPAGLIFLOZIN

TABLET;ORAL

EMPAGLIFLOZIN

		@ ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022	Jan	DISC
		@	25MG	A212138	002	Aug 03, 2022	Jan	DISC
		JARDIANCE						
+		BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Jan	CTEC
+	!		25MG	N204629	002	Aug 01, 2014	Jan	CTEC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

>A>	AP	SAGENT PHARMS INC	50MG/ML (50MG/ML)	A214528	001	Mar 09, 2023	Feb	NEWA
-----	----	-------------------	-------------------	---------	-----	--------------	-----	------

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

>D>	AP2	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb	CHRS
>A>	AP2	!	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb	CHRS
		VELETRI						
>D>	AP2	+	ACTELION	N022260	002	Jun 28, 2012	Feb	CHRS
>A>	AP2	+		N022260	002	Jun 28, 2012	Feb	CHRS

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

>D>	AA	+	VALIDUS PHARMS	50,000 IU	N003444	001		Feb	CHRS
>A>	AA	+		50,000 IU	N003444	001		Feb	CHRS
			ERGOCALCIFEROL						
>D>	AA		ALEMBIC LABS	50,000 IU	A040833	001	May 20, 2009	Feb	CAHN
>A>	AA		CHARTWELL RX	50,000 IU	A040833	001	May 20, 2009	Feb	CAHN
>D>	AA		STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Feb	CHRS
>A>	AA	!		50,000 IU	A090455	001	Aug 03, 2010	Feb	CHRS

ERYTHROMYCIN

TABLET;ORAL

ERYTHROMYCIN

	AB		ARBOR PHARMS LLC	500MG	A061621	002		Jan	CHRS
	AB	!	CADILA PHARMS LTD	500MG	A213628	002	Jun 28, 2021	Jan	CHRS
>A>	AB		ZYDUS	250MG	A212693	001	Mar 07, 2023	Feb	NEWA
>A>	AB			500MG	A212693	002	Mar 07, 2023	Feb	NEWA

ESCITALOPRAM OXALATE

SOLUTION;ORAL

LEXAPRO

+ @ ABBVIE EQ 5MG BASE/5ML N021365 001 Nov 27, 2002 Jan CAHN

TABLET;ORAL

ESCITALOPRAM OXALATE

>A> @ DASH PHARMS EQ 5MG BASE A077550 001 May 14, 2015 Feb CAHN  
 >A> @ EQ 10MG BASE A077550 002 May 14, 2015 Feb CAHN  
 >A> @ EQ 20MG BASE A077550 003 May 14, 2015 Feb CAHN  
 >D> @ MYLAN EQ 5MG BASE A077550 001 May 14, 2015 Feb CAHN  
 >D> @ EQ 10MG BASE A077550 002 May 14, 2015 Feb CAHN  
 >D> @ EQ 20MG BASE A077550 003 May 14, 2015 Feb CAHN

LEXAPRO

AB + ABBVIE EQ 5MG BASE N021323 001 Aug 14, 2002 Jan CAHN  
 AB + EQ 10MG BASE N021323 002 Aug 14, 2002 Jan CAHN  
 AB +! EQ 20MG BASE N021323 003 Aug 14, 2002 Jan CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

AP +! BAXTER HLTHCARE 2GM/100ML N019386 005 Jan 27, 2003 Jan CTEC  
 BREVIBLOC IN PLASTIC CONTAINER

AP +! BAXTER HLTHCARE 1GM/100ML N019386 004 Feb 16, 2001 Jan CTEC  
 ESMOLOL HYDROCHLORIDE

AP AMNEAL 1GM/100ML A216603 001 Dec 13, 2022 Jan CPOT  
 AP 2GM/100ML A216603 002 Dec 13, 2022 Jan CPOT  
 AP EUGIA PHARMA 1GM/100ML A216244 001 Mar 21, 2022 Jan CPOT  
 AP 2GM/100ML A216244 002 Mar 21, 2022 Jan CPOT  
 AP HQ SPCLT PHARMA 1GM/100ML A214172 001 Dec 02, 2022 Jan CPOT  
 AP 2GM/100ML A214172 002 Dec 02, 2022 Jan CPOT  
 AP MYLAN LABS LTD 1GM/100ML A206608 001 Jun 08, 2018 Jan CPOT  
 AP 2GM/100ML A206608 002 Jun 08, 2018 Jan CPOT  
 AP SAGENT PHARMS INC 1GM/100ML A207107 001 Jun 08, 2018 Jan CPOT  
 AP 2GM/100ML A207107 002 Jun 08, 2018 Jan CPOT

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

>D> AB ACTAVIS LABS FL INC EQ 20MG BASE;375MG A204470 001 Aug 24, 2022 Feb DISC  
 >A> @ EQ 20MG BASE;375MG A204470 001 Aug 24, 2022 Feb DISC  
 >D> AB EQ 20MG BASE;500MG A204470 002 Aug 24, 2022 Feb DISC  
 >A> @ EQ 20MG BASE;500MG A204470 002 Aug 24, 2022 Feb DISC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP EUGIA PHARMA EQ 40MG BASE/VIAL A204657 002 Aug 10, 2016 Jan CHRS

ESTRADIOL

INSERT;VAGINAL

IMVEXXY

+ MAYNE PHARMA 0.004MG N208564 001 May 29, 2018 Jan CAHN  
 +! 0.01MG N208564 002 May 29, 2018 Jan CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

@ AMNEAL PHARMS 0.02MG;0.1MG A201108 001 Feb 05, 2014 Jan DISC  
 @ 0.03MG;0.15MG A201095 001 Dec 08, 2014 Jan DISC  
 >A> AB1 HETERO LABS 0.02MG;0.1MG A212298 001 Feb 13, 2023 Feb NEWA  
 AB LUPIN LTD 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A200248 001 Nov 19, 2015 Jan CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

PIRMELLA 1/35

@ LUPIN LTD 0.035MG;1MG A201512 001 Apr 24, 2013 Jan DISC

PIRMELLA 7/7/7

@ LUPIN LTD 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A201510 001 Apr 24, 2013 Jan DISC



ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL							
>A>		HAILEY 24 FE						
>A>	AB	! GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Feb	CTNA
>D>		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
>D>	AB	! GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Feb	CTNA

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET;ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL						
		@ AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A203870	001	Nov 12, 2015	Jan	DISC
			15MG,0.25MG					

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

	RING;VAGINAL							
		ANNOVERA						
		+! MAYNE PHARMA	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Jan	CAHN

ETOPOSIDE

	INJECTABLE; INJECTION							
		ETOPOSIDE						
>A>		@ DASH PHARMS NATCO	20MG/ML	A203507	001	Nov 20, 2017	Feb	CAHN
>D>		@ MYLAN LABS LTD	20MG/ML	A203507	001	Nov 20, 2017	Feb	CAHN

EXEMESTANE

	TABLET;ORAL							
		EXEMESTANE						
>D>	AB	ALVOGEN	25MG	A200898	001	Jul 28, 2014	Feb	DISC
>A>		@	25MG	A200898	001	Jul 28, 2014	Feb	DISC

FAMOTIDINE

	TABLET;ORAL							
		FAMOTIDINE						
AB		VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan	CAHN
AB			40MG	A215630	002	Jan 07, 2022	Jan	CAHN

FEBUXOSTAT

	TABLET;ORAL							
		FEBUXOSTAT						
AB		ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan	CAHN
AB			80MG	A205443	002	Jan 09, 2023	Jan	CAHN

FENOFIBRATE

	TABLET;ORAL							
		FENOFIBRATE						
>D>	AB	ALEMBIC LABS	54MG	A209660	001	Feb 11, 2019	Feb	CAHN
>D>	AB		160MG	A209660	002	Feb 11, 2019	Feb	CAHN
>A>	AB	CHARTWELL RX	54MG	A209660	001	Feb 11, 2019	Feb	CAHN
>A>	AB		160MG	A209660	002	Feb 11, 2019	Feb	CAHN

FENTANYL

	FILM, EXTENDED RELEASE;TRANSDERMAL							
		FENTANYL-100						
AB		ZYDUS NOVELTECH INC	100MCG/HR	A209655	008	Jan 24, 2023	Jan	NEWA
		FENTANYL-12						
AB		ZYDUS NOVELTECH INC	12.5MCG/HR	A209655	001	Jan 24, 2023	Jan	NEWA
		FENTANYL-25						
AB		ZYDUS NOVELTECH INC	25MCG/HR	A209655	002	Jan 24, 2023	Jan	NEWA
		FENTANYL-37						
AB		ZYDUS NOVELTECH INC	37.5MCG/HR	A209655	003	Jan 24, 2023	Jan	NEWA
		FENTANYL-50						
AB		ZYDUS NOVELTECH INC	50MCG/HR	A209655	004	Jan 24, 2023	Jan	NEWA
		FENTANYL-62						
AB		ZYDUS NOVELTECH INC	62.5MCG/HR	A209655	005	Jan 24, 2023	Jan	NEWA
		FENTANYL-75						
AB		ZYDUS NOVELTECH INC	75MCG/HR	A209655	006	Jan 24, 2023	Jan	NEWA
		FENTANYL-87						
AB		MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Jan	CTEC
AB		ZYDUS NOVELTECH INC	87.5MCG/HR	A209655	007	Jan 24, 2023	Jan	NEWA

FENTANYL CITRATE

		INJECTABLE; INJECTION						
		FENTANYL CITRATE						
	AP	+! HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023	Jan	NEWA
		+!	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jan	CTNA
		SOLUTION; INTRAVENOUS						
		FENTANYL CITRATE						
	>A>	+! EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	Feb	NEWA
	>A>	+!	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	Feb	NEWA

FESOTERODINE FUMARATE

		TABLET, EXTENDED RELEASE; ORAL						
		FESOTERODINE FUMARATE						
	>D> AB	LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb	DISC
	>A>	@	4MG	A204983	001	Jan 05, 2023	Feb	DISC
	>D> AB		8MG	A204983	002	Jan 05, 2023	Feb	DISC
	>A>	@	8MG	A204983	002	Jan 05, 2023	Feb	DISC

FINAFLOXACIN

		SUSPENSION/DROPS; OTIC						
		XTORO						
		+ @ FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Jan	CAHN

FINGOLIMOD HYDROCHLORIDE

		CAPSULE; ORAL						
		FINGOLIMOD HYDROCHLORIDE						
	AB	BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jan	CMFD

FINGOLIMOD LAURYL SULFATE

		TABLET, ORALLY DISINTEGRATING; ORAL						
		TASCENSO ODT						
		+ CYCLE	EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Jan	CAHN
		+!	EQ 0.5MG BASE	N214962	002	Dec 09, 2022	Jan	CAHN

FLUDARABINE PHOSPHATE

		INJECTABLE; INJECTION						
		FLUDARABINE PHOSPHATE						
	AP2	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jan	CTEC
	AP1	AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jan	CTEC
	AP1	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan	CTEC
	AP		50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan	CHRS
	AP1	SAGENT PHARMS INC	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan	CTEC
	AP2	+! SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan	CTEC

FLUDEOXYGLUCOSE F-18

		INJECTABLE; INTRAVENOUS						
		FLUDEOXYGLUCOSE F18						
		@ ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan	DISC

FLUOCINONIDE

		CREAM; TOPICAL						
		FLUOCINONIDE						
	>D> AB1	AMNEAL	0.05%	A210554	001	Aug 21, 2018	Feb	CHRS
	>A> AB1	!	0.05%	A210554	001	Aug 21, 2018	Feb	CHRS
	>D> AB1	+! TARO	0.05%	N019117	001	Jun 26, 1984	Feb	DISC
	>A>	+ @	0.05%	N019117	001	Jun 26, 1984	Feb	DISC

FLUOROMETHOLONE

		SUSPENSION/DROPS; OPHTHALMIC						
		FML						
		+! ABBVIE	0.1%	N016851	002	Jul 28, 1982	Jan	CAHN
		FML FORTE						
		+! ABBVIE	0.25%	N019216	001	Apr 23, 1986	Jan	CAHN

FLUOROURACILINJECTABLE; INJECTION  
FLUOROURACIL

>A>	AP	ALEMBIC	2.5GM/50ML (50MG/ML)	A217295	001	Mar 03, 2023	Feb NEWA
-----	----	---------	----------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDESOLUTION; ORAL  
FLUOXETINE HYDROCHLORIDE

AA		XTTRIUM LABS INC	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Jan CAHN
----	--	------------------	------------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATETABLET; ORAL  
LUVOX

AB	+	ANI PHARMS	25MG	N021519	001	Dec 20, 2007	Jan CRLD
AB	+		50MG	N021519	002	Dec 20, 2007	Jan CRLD
AB	+		100MG	N021519	003	Dec 20, 2007	Jan CRLD

FUROSEMIDESOLUTION; ORAL  
FUROSEMIDE

@	XTTRIUM LABS INC	10MG/ML	A070655	001	Oct 02, 1987	Jan CAHN
---	------------------	---------	---------	-----	--------------	----------

GABAPENTINSOLUTION; ORAL  
GABAPENTIN

AA		RUBICON	250MG/5ML	A216492	001	Jan 18, 2023	Jan NEWA
----	--	---------	-----------	---------	-----	--------------	----------

GADOTERATE MEGLUMINESOLUTION; INTRAVENOUS  
GADOTERATE MEGLUMINE

>A>	AP	HENGRUI PHARMA	37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022	Feb CMS1
-----	----	----------------	----------------------------	---------	-----	--------------	----------

GANIRELIX ACETATEINJECTABLE; INJECTION  
GANIRELIX ACETATE

>A>	AP	GLAND PHARMA LTD	250MCG/0.5ML	A215658	001	Feb 28, 2023	Feb NEWA
-----	----	------------------	--------------	---------	-----	--------------	----------

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC  
ZYMAXID

AT	+	ABBVIE	0.5%	N022548	001	May 18, 2010	Jan CAHN
----	---	--------	------	---------	-----	--------------	----------

GEFITINIBTABLET; ORAL  
GEFITINIB

>A>	AB	QILU PHARM HAINAN	250MG	A211591	001	Feb 13, 2023	Feb NEWA
-----	----	-------------------	-------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

>A>	AP	HIKMA	200MG/5.26ML (38MG/ML)	A213175	001	Mar 07, 2023	Feb NEWA
>A>	AP		1GM/26.3ML (38MG/ML)	A213175	002	Mar 07, 2023	Feb NEWA
>A>	AP		2GM/52.6ML (38MG/ML)	A213175	003	Mar 07, 2023	Feb NEWA

GENTAMICIN SULFATEOINTMENT; OPHTHALMIC  
GENTAMICIN SULFATE

>D>	AT	!	AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Feb DISC
>A>		@		EQ 0.3% BASE	A064093	001	Aug 31, 1995	Feb DISC
>D>	AT		FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CTEC
>A>		!		EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CTEC

SOLUTION/DROPS; OPHTHALMIC  
GENOPTIC

>D>	AT	!	ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Feb DISC
>A>		@		EQ 0.3% BASE	A062452	001	Oct 10, 1984	Feb DISC
			GEN TAK					
>D>	AT		AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb DISC
>A>		@		EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb DISC
			GENTAMICIN SULFATE					
>D>	AT		SANDOZ INC	EQ 0.3% BASE	A062196	001		Feb CHRS

SOLUTION/DROPS;OPHTHALMIC									
GENTAMICIN SULFATE									
>A>	AT	!	EQ 0.3% BASE		A062196	001			Feb CHRS
<u>GENTAMICIN SULFATE; PREDNISOLONE ACETATE</u>									
OINTMENT;OPHTHALMIC									
PRED-G									
	+	@	ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989		Jan DISC
<u>GLIPIZIDE; METFORMIN HYDROCHLORIDE</u>									
TABLET;ORAL									
GLIPIZIDE AND METFORMIN HYDROCHLORIDE									
>A>		@	DASH PHARMS	2.5MG;250MG	A078083	001	Apr 12, 2007		Feb CAHN
>A>		@		2.5MG;500MG	A078083	002	Apr 12, 2007		Feb CAHN
>A>		@		5MG;500MG	A078083	003	Apr 12, 2007		Feb CAHN
>D>		@	MYLAN	2.5MG;250MG	A078083	001	Apr 12, 2007		Feb CAHN
>D>		@		2.5MG;500MG	A078083	002	Apr 12, 2007		Feb CAHN
>D>		@		5MG;500MG	A078083	003	Apr 12, 2007		Feb CAHN
<u>GLUCAGON</u>									
SOLUTION;SUBCUTANEOUS									
GVOKE PFS									
	+	@	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019		Jan DISC
<u>GLYCEROL PHENYLBUTYRATE</u>									
LIQUID;ORAL									
RAVICTI									
	+	!	HORIZON THERAP US	1.1GM/ML	N203284	001	Feb 01, 2013		Jan CAHN
<u>GLYCOPYRROLATE</u>									
INJECTABLE;INJECTION									
GLYCOPYRROLATE									
AP			LUPIN LTD	0.2MG/ML	A213655	001	Feb 07, 2023		Jan NEWA
>A>	AP		MANKIND PHARMA	0.2MG/ML	A217354	001	Feb 27, 2023		Feb NEWA
TABLET;ORAL									
GLYCOPYRROLATE									
>A>	AA		ALEMBIC	1MG	A203657	001	Nov 30, 2018		Feb CAHN
>A>	AA			2MG	A203657	002	Nov 30, 2018		Feb CAHN
>D>	AA		ALEMBIC LABS	1MG	A203657	001	Nov 30, 2018		Feb CAHN
>D>	AA			2MG	A203657	002	Nov 30, 2018		Feb CAHN
	AA		AUROBINDO PHARMA	1MG	A202675	001	Apr 15, 2013		Jan CAHN
	AA			2MG	A202675	002	Oct 30, 2018		Jan CAHN
>A>	<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE</u>								
>A>	SOLUTION;INTRAVENOUS								
>A>	PREVDUO								
>A>		+	!	SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb NEWA
<u>HALOPERIDOL</u>									
TABLET;ORAL									
HALOPERIDOL									
		@	ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022		Jan DISC
		@		1MG	A200854	002	Jul 01, 2022		Jan DISC
		@		2MG	A200854	003	Jul 01, 2022		Jan DISC
		@		5MG	A200854	004	Jul 01, 2022		Jan DISC
		@		10MG	A200854	005	Jul 01, 2022		Jan DISC
		@		20MG	A200854	006	Jul 01, 2022		Jan DISC
AB			ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023		Jan NEWA
AB				1MG	A077580	002	Jan 17, 2023		Jan NEWA
AB				2MG	A077580	006	Jan 17, 2023		Jan NEWA
<u>HEPARIN SODIUM</u>									
INJECTABLE;INJECTION									
HEPARIN SODIUM									
>D>		@	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020		Feb CMFD
>A>	AP			5,000 UNITS/ML	A212061	001	Jul 15, 2020		Feb CMFD
HEPARIN SODIUM PRESERVATIVE FREE									
>D>		@	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020		Feb CMFD
>A>	AP			10,000 UNITS/ML	A212060	001	Apr 02, 2020		Feb CMFD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
HYDRALAZINE HYDROCHLORIDE

>A> AP EUGIA PHARMA 20MG/ML A215147 001 Feb 13, 2023 Feb NEWA

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL  
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>A> AB ZYDUS PHARMS 12.5MG; 20MG A206377 001 Feb 24, 2023 Feb NEWA  
>A> AB 12.5MG; 40MG A206377 002 Feb 24, 2023 Feb NEWA  
>A> AB 25MG; 40MG A206377 003 Feb 24, 2023 Feb NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL  
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB APOTEX 12.5MG; EQ 10MG BASE A091524 001 Mar 12, 2013 Jan CAHN  
AB 12.5MG; EQ 20MG BASE A091524 002 Mar 12, 2013 Jan CAHN  
AB 25MG; EQ 20MG BASE A091524 003 Mar 12, 2013 Jan CAHN

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC  
PAREMYD

>D> +! AKORN 1%; 0.25% N019261 001 Jan 30, 1992 Feb DISC  
>A> + @ 1%; 0.25% N019261 001 Jan 30, 1992 Feb DISC

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC  
LACRISERT

+! BAUSCH 5MG N018771 001 Jan CAHN  
+! BAUSCH AND LOMB INC 5MG N018771 001 Jan CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
HYDROXYZINE HYDROCHLORIDE

>D> ! AM REGENT 25MG/ML A087408 001 Feb CRLD  
>A> +! 25MG/ML A087408 001 Feb CRLD  
>D> ! 50MG/ML A087408 002 Feb CRLD  
>A> +! 50MG/ML A087408 002 Feb CRLD

TABLET; ORAL  
HYDROXYZINE HYDROCHLORIDE

AB CHARTWELL RX 10MG A040804 001 Jun 30, 2008 Jan CAHN  
AB 25MG A040804 002 Jun 30, 2008 Jan CAHN  
AB 50MG A040804 003 Jun 30, 2008 Jan CAHN

ICOSAPENT ETHYL

CAPSULE; ORAL  
ICOSAPENT ETHYL

>A> AB DR REDDYS 500MG A209499 002 Mar 08, 2023 Feb NEWA  
>A> AB HIKMA 500MG A209457 002 Mar 08, 2023 Feb NEWA

IMATINIB MESYLATE

TABLET; ORAL  
IMATINIB MESYLATE

AB CHARTWELL RX EQ 100MG BASE A208429 001 Jan 17, 2019 Jan CAHN  
AB EQ 400MG BASE A208429 002 Jan 17, 2019 Jan CAHN

IMIQUIMOD

CREAM; TOPICAL  
ALDARA

>D> >D> AB +! BAUSCH 5% N020723 001 Feb 27, 1997 Feb DISC  
>A> + @ 5% N020723 001 Feb 27, 1997 Feb DISC

IMIQUIMOD

>D> AB GLENMARK GENERICS 5% A201994 001 Mar 06, 2012 Feb CHRS  
>A> AB ! 5% A201994 001 Mar 06, 2012 Feb CHRS

INDOMETHACIN

CAPSULE; ORAL		INDOMETHACIN					
>D>	@ CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CMFD
>A>	AB	25MG	N018829	002	Aug 06, 1984	Feb	CMFD
>D>	@	50MG	N018829	001	Aug 06, 1984	Feb	CMFD
>A>	AB	50MG	N018829	001	Aug 06, 1984	Feb	CMFD

IOPAMIDOL

INJECTABLE; INJECTION		IOPAMIDOL						
>A>	AP	HAINAN POLY	41%	A215382	001	Feb 27, 2023	Feb	NEWA
>A>	AP		61%	A215382	002	Feb 27, 2023	Feb	NEWA
ISOVUE-M 200								
>D>	+!	BRACCO	41%	N018735	001	Dec 31, 1985	Feb	CTEC
>A>	AP	+!	41%	N018735	001	Dec 31, 1985	Feb	CTEC
ISOVUE-M 300								
>D>	+!	BRACCO	61%	N018735	004	Dec 31, 1985	Feb	CTEC
>A>	AP	+!	61%	N018735	004	Dec 31, 1985	Feb	CTEC

ISONIAZID

TABLET; ORAL		LANIAZID					
>A>	@ CHARTWELL MOLECULAR	50MG	A080140	001		Feb	CAHN
>A>	@	100MG	A080140	002		Feb	CAHN
>D>	@ LANNETT	50MG	A080140	001		Feb	CAHN
>D>	@	100MG	A080140	002		Feb	CAHN

IVERMECTIN

CREAM; TOPICAL		IVERMECTIN					
	@ ZYDUS	1%	A215210	001	Aug 02, 2022	Jan	DISC

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		KETAMINE HYDROCHLORIDE					
AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan	NEWA
AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan	NEWA
AP	GLAND PHARMA LTD	EQ 10MG BASE/ML	A216809	001	Jan 24, 2023	Jan	NEWA
AP		EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan	NEWA
AP		EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan	NEWA

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC		ACULAR						
AT	+! ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan	CAHN	
KETOROLAC TROMETHAMINE								
	@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan	DISC	
TABLET; ORAL		KETOROLAC TROMETHAMINE						
>A>	AB	BIONPHARMA INC	10MG	A216759	001	Feb 23, 2023	Feb	NEWA
>A>	AB	LEADING	10MG	A215745	001	Feb 23, 2023	Feb	NEWA

LACOSAMIDE

SOLUTION; INTRAVENOUS		LACOSAMIDE						
>A>	AP	MSN	200MG/20ML (10MG/ML)	A215979	001	Feb 09, 2023	Feb	NEWA
SOLUTION; ORAL		LACOSAMIDE						
AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Jan	NEWA	
TABLET; ORAL		LACOSAMIDE						
	@ ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jan	DISC	
	@	100MG	A205011	002	Jul 12, 2022	Jan	DISC	
	@	150MG	A205011	003	Jul 12, 2022	Jan	DISC	
	@	200MG	A205011	004	Jul 12, 2022	Jan	DISC	

LACTULOSESOLUTION;ORAL, RECTAL  
LACTULOSE

>D>	@ BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Feb	CMFD
>A>	AA	10GM/15ML	A076645	001	Jul 28, 2003	Feb	CMFD

LAMIVUDINE; ZIDOVUDINETABLET;ORAL  
LAMIVUDINE AND ZIDOVUDINE

>D>	AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418	001	May 15, 2012	Feb	DISC
>A>		@	150MG;300MG	A202418	001	May 15, 2012	Feb	DISC

LAMOTRIGINETABLET;ORAL  
LAMOTRIGINE

	@	CHARTWELL MOLECULAR	25MG	A077783	001	Nov 01, 2010	Jan	CAHN
	@		100MG	A077783	002	Nov 01, 2010	Jan	CAHN
	@		150MG	A077783	003	Nov 01, 2010	Jan	CAHN
	@		200MG	A077783	004	Nov 01, 2010	Jan	CAHN

LATANOPROSTSOLUTION/DROPS;OPHTHALMIC  
LATANOPROST

	@	AKORN	0.005%	A090887	001	Jul 19, 2011	Jan	DISC
--	---	-------	--------	---------	-----	--------------	-----	------

LENALIDOMIDECAPSULE;ORAL  
LENALIDOMIDE

>A>	AB	APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb	NEWA
>A>	AB		20MG	A211022	006	Mar 07, 2023	Feb	NEWA
>A>	AB	ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb	NEWA
>A>	AB		20MG	A201452	006	Mar 06, 2023	Feb	NEWA
>A>	AB	CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb	NEWA
>A>	AB		20MG	A210435	005	Mar 06, 2023	Feb	NEWA
>A>	AB	EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb	NEWA
>A>	AB		5MG	A213885	002	Mar 06, 2023	Feb	NEWA
>A>	AB		10MG	A213885	003	Mar 06, 2023	Feb	NEWA
>A>	AB		15MG	A213885	004	Mar 06, 2023	Feb	NEWA
>A>	AB		20MG	A213885	005	Mar 06, 2023	Feb	NEWA
>A>	AB		25MG	A213885	006	Mar 06, 2023	Feb	NEWA
>A>	AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb	NEWA
>A>	AB		20MG	A210480	006	Mar 06, 2023	Feb	NEWA
>A>	AB	MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb	NEWA
>A>	AB		20MG	A213912	006	Mar 06, 2023	Feb	NEWA
>A>	AB	SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb	NEWA
	AB		5MG	A211846	001	Feb 08, 2023	Jan	NEWA
	AB		10MG	A211846	002	Feb 08, 2023	Jan	NEWA
	AB		15MG	A211846	003	Feb 08, 2023	Jan	NEWA
>A>	AB		20MG	A211846	006	Mar 06, 2023	Feb	NEWA
	AB		25MG	A211846	004	Feb 08, 2023	Jan	NEWA
>A>	AB	TORRENT	10MG	A213405	001	Feb 17, 2023	Feb	NEWA
>A>	AB		25MG	A213405	002	Feb 17, 2023	Feb	NEWA
>A>	AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb	NEWA
>A>	AB		20MG	A210154	006	Mar 06, 2023	Feb	NEWA

LETROZOLETABLET;ORAL  
LETROZOLE

>A>	@	CHARTWELL RX	2.5MG	A202716	001	May 16, 2013	Feb	CAHN
>D>	@	HENGRUI PHARMA	2.5MG	A202716	001	May 16, 2013	Feb	CAHN

LEUPROLIDE ACETATEPOWDER;SUBCUTANEOUS  
ELIGARD KIT

>A>	+	TOLMAR	7.5MG	N021343	001	Jan 23, 2002	Feb	CAHN
>A>	+		22.5MG	N021379	001	Jul 24, 2002	Feb	CAHN
>A>	+		30MG	N021488	001	Feb 13, 2003	Feb	CAHN
>A>	+		45MG	N021731	001	Dec 14, 2004	Feb	CAHN
>D>	+	TOLMAR THERAP	7.5MG	N021343	001	Jan 23, 2002	Feb	CAHN
>D>	+		22.5MG	N021379	001	Jul 24, 2002	Feb	CAHN
>D>	+		30MG	N021488	001	Feb 13, 2003	Feb	CAHN
>D>	+		45MG	N021731	001	Dec 14, 2004	Feb	CAHN

LEVETIRACETAM

INJECTABLE; INTRAVENOUS  
LEVETIRACETAM IN SODIUM CHLORIDE

AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan	NEWA
AP		1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Jan	NEWA
AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan	NEWA

SOLUTION; ORAL  
LEVETIRACETAM

>D>	AA	AIPING PHARM INC	100MG/ML	A090079	001	Apr 11, 2012	Feb	CAHN
>A>	AA	ALEMBIC	100MG/ML	A203067	001	May 09, 2013	Feb	CAHN
>D>	AA	ALEMBIC LABS	100MG/ML	A203067	001	May 09, 2013	Feb	CAHN
>A>	AA	QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Feb	CAHN

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC  
LEVOFLOXACIN

@	AKORN	0.5%	A090268	001	Dec 20, 2010	Jan	DISC
!	RISING	0.5%	A077700	001	Dec 20, 2010	Jan	CTEC

LEVORPHANOL TARTRATE

TABLET; ORAL  
LEVORPHANOL TARTRATE

AB	HIKMA	2MG	A074278	001	Mar 31, 2000	Jan	CMFD
----	-------	-----	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL  
LEVOTHYROXINE SODIUM

AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan	NEWA
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan	NEWA
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan	NEWA
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan	NEWA
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan	NEWA
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan	NEWA
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan	NEWA
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan	NEWA
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan	NEWA
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan	NEWA
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan	NEWA
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan	NEWA
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan	CTEC
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan	CTEC
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan	CTEC
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan	CTEC
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan	CTEC
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan	CTEC
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan	CTEC
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan	CTEC
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan	CTEC
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan	CTEC
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan	CTEC
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan	CTEC

LINACLOTIDE

CAPSULE; ORAL  
LINACLOTIDE

AB	AUROBINDO PHARMA	145MCG	A209611	001	Feb 07, 2023	Jan	NEWA
AB		290MCG	A209611	002	Feb 07, 2023	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL  
LOPERAMIDE HYDROCHLORIDE

AB	RUBICON	2MG	A216876	001	Jan 26, 2023	Jan	NEWA
----	---------	-----	---------	-----	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL  
LOSARTAN POTASSIUM

>A>	AB	GRANULES	25MG	A215959	001	Feb 23, 2023	Feb	NEWA
>A>	AB		50MG	A215959	002	Feb 23, 2023	Feb	NEWA
>A>	AB		100MG	A215959	003	Feb 23, 2023	Feb	NEWA



LUBIPROSTONE

CAPSULE;ORAL  
LUBIPROSTONE

AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan	CMFD
AB		24MCG	A209450	002	Nov 30, 2021	Jan	CMFD

LURASIDONE HYDROCHLORIDE

TABLET;ORAL  
LURASIDONE HYDROCHLORIDE

>D>	@ AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb	CMFD
>A>	AB	20MG	A208002	001	Jan 03, 2019	Feb	CMFD
>D>	@	40MG	A208002	002	Jan 03, 2019	Feb	CMFD
>A>	AB	40MG	A208002	002	Jan 03, 2019	Feb	CMFD
>D>	@	60MG	A208002	003	Jan 03, 2019	Feb	CMFD
>A>	AB	60MG	A208002	003	Jan 03, 2019	Feb	CMFD
>D>	@	80MG	A208002	004	Jan 03, 2019	Feb	CMFD
>A>	AB	80MG	A208002	004	Jan 03, 2019	Feb	CMFD
>D>	@	120MG	A208002	005	Jan 03, 2019	Feb	CMFD
>A>	AB	120MG	A208002	005	Jan 03, 2019	Feb	CMFD
>A>	AB	AVET LIFESCIENCES	A208058	005	Feb 28, 2023	Feb	NEWA
>D>	@ LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb	CMFD
>A>	AB	20MG	A208031	001	Jan 03, 2019	Feb	CMFD
>D>	@	40MG	A208031	002	Jan 03, 2019	Feb	CMFD
>A>	AB	40MG	A208031	002	Jan 03, 2019	Feb	CMFD
>D>	@	60MG	A208031	003	Jan 03, 2019	Feb	CMFD
>A>	AB	60MG	A208031	003	Jan 03, 2019	Feb	CMFD
>D>	@	80MG	A208031	004	Jan 03, 2019	Feb	CMFD
>A>	AB	80MG	A208031	004	Jan 03, 2019	Feb	CMFD
>D>	@	120MG	A208031	005	Jan 03, 2019	Feb	CMFD
>A>	AB	120MG	A208031	005	Jan 03, 2019	Feb	CMFD
>D>	@ PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb	CMFD
>A>	AB	20MG	A212091	001	Dec 28, 2020	Feb	CMFD
>D>	@	40MG	A212091	002	Dec 28, 2020	Feb	CMFD
>A>	AB	40MG	A212091	002	Dec 28, 2020	Feb	CMFD
>D>	@	60MG	A212091	003	Dec 28, 2020	Feb	CMFD
>A>	AB	60MG	A212091	003	Dec 28, 2020	Feb	CMFD
>D>	@	80MG	A212091	004	Dec 28, 2020	Feb	CMFD
>A>	AB	80MG	A212091	004	Dec 28, 2020	Feb	CMFD
>D>	@	120MG	A212091	005	Dec 28, 2020	Feb	CMFD
>A>	AB	120MG	A212091	005	Dec 28, 2020	Feb	CMFD
>D>	@ TORRENT	20MG	A208055	001	Jan 03, 2019	Feb	CMFD
>A>	AB	20MG	A208055	001	Jan 03, 2019	Feb	CMFD
>D>	@	40MG	A208055	002	Jan 03, 2019	Feb	CMFD
>A>	AB	40MG	A208055	002	Jan 03, 2019	Feb	CMFD
>D>	@	80MG	A208055	003	Jan 03, 2019	Feb	CMFD
>A>	AB	80MG	A208055	003	Jan 03, 2019	Feb	CMFD
>D>	@	120MG	A208055	004	Jan 03, 2019	Feb	CMFD
>A>	AB	120MG	A208055	004	Jan 03, 2019	Feb	CMFD

MAGNESIUM SULFATE

INJECTABLE;INJECTION  
MAGNESIUM SULFATE IN PLASTIC CONTAINER

>A>	AP	AMNEAL	2GM/50ML (40MG/ML)	A216597	001	Feb 15, 2023	Feb	NEWA
>A>	AP		4GM/100ML (40MG/ML)	A216597	002	Feb 15, 2023	Feb	NEWA

MECLOFENAMATE SODIUM

CAPSULE;ORAL  
MECLOFENAMATE SODIUM

@	CHARTWELL RX	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan	CAHN
@		EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan	CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL  
MEGESTROL ACETATE

	@	BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jan	DISC
AB		XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jan	CAHN

MELOXICAMTABLET; ORAL  
MELOXICAM

>D>	AB	APOTEX INC	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
>D>	AB		15MG	A077882	002	Jul 20, 2006	Feb CAHN
>A>	AB	COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
>A>	AB		15MG	A077882	002	Jul 20, 2006	Feb CAHN

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
MEMANTINE HYDROCHLORIDE

>D>	AB	ANI PHARMS	28MG	A205365	004	Feb 28, 2020	Feb DISC
>A>		@	28MG	A205365	004	Feb 28, 2020	Feb DISC
		NAMENDA XR					
>A>	AB	+ ABBVIE	7MG	N022525	001	Jun 21, 2010	Feb CAHN
>A>	AB	+	14MG	N022525	002	Jun 21, 2010	Feb CAHN
>A>	AB	+	21MG	N022525	003	Jun 21, 2010	Feb CAHN
>A>	AB	+	28MG	N022525	004	Jun 21, 2010	Feb CAHN
>D>	AB	+ ALLERGAN	7MG	N022525	001	Jun 21, 2010	Feb CAHN
>D>	AB	+	14MG	N022525	002	Jun 21, 2010	Feb CAHN
>D>	AB	+	21MG	N022525	003	Jun 21, 2010	Feb CAHN
>D>	AB	+	28MG	N022525	004	Jun 21, 2010	Feb CAHN

TABLET; ORAL  
NAMENDA

>A>	AB	+ ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb CAHN
>A>	AB	+	10MG	N021487	002	Oct 16, 2003	Feb CAHN
>D>	AB	+ ALLERGAN	5MG	N021487	001	Oct 16, 2003	Feb CAHN
>D>	AB	+	10MG	N021487	002	Oct 16, 2003	Feb CAHN

MESALAMINECAPSULE, DELAYED RELEASE; ORAL  
DELZICOL

>A>	AB	+	400MG	N204412	001	Feb 01, 2013	Feb CAHN
>D>	AB	+	400MG	N204412	001	Feb 01, 2013	Feb CAHN

SUPPOSITORY; RECTAL  
CANASA

>A>		@ ABBVIE	500MG	N021252	001	Jan 05, 2001	Feb CAHN
>A>	AB	+	1GM	N021252	002	Nov 05, 2004	Feb CAHN
>D>		@ ALLERGAN	500MG	N021252	001	Jan 05, 2001	Feb CAHN
>D>	AB	+	1GM	N021252	002	Nov 05, 2004	Feb CAHN

METAXALONETABLET; ORAL  
METAXALONE

>D>		+ @ PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Feb CMFD
>A>		+	640MG	N022503	001	Jun 01, 2015	Feb CMFD

METHOCARBAMOLSOLUTION; IM-IV  
METHOCARBAMOL

>D>	AP	BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Feb DISC
>A>		@	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Feb DISC

TABLET; ORAL  
METHOCARBAMOL

>D>	AA	ACME LABS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
>D>	AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN
>A>	AA	AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb NEWA
>D>		@	750MG	A213967	001	Aug 12, 2020	Feb CMFD
>A>	AA		750MG	A213967	001	Aug 12, 2020	Feb CMFD
>A>	AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
>A>	AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN

METOCLOPRAMIDE HYDROCHLORIDESOLUTION; ORAL  
METOCLOPRAMIDE HYDROCHLORIDE

AA	!	XTTRIUM LABS INC	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Jan CAHN
----	---	------------------	-----------------	---------	-----	--------------	----------

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

AB	COSETTE	1%	A216692	001	Jan 23, 2023	Jan NEWA	
>D>	AB	TOLMAR	1%	A090903	001	Jul 22, 2011	Feb DISC
>A>	@	1%	A090903	001	Jul 22, 2011	Feb DISC	

TABLET; ORAL

METRONIDAZOLE

>A>	AB	ALEMBIC	250MG	A208681	001	Jun 20, 2017	Feb CAHN
>A>	AB		500MG	A208681	002	Jun 20, 2017	Feb CAHN
>D>	AB	ALEMBIC LABS	250MG	A208681	001	Jun 20, 2017	Feb CAHN
>D>	AB		500MG	A208681	002	Jun 20, 2017	Feb CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

>D>	AB	AUCTA	150MG	A215315	001	Aug 26, 2022	Feb CAHN
>D>	AB		200MG	A215315	002	Aug 26, 2022	Feb CAHN
>D>	AB		250MG	A215315	003	Aug 26, 2022	Feb CAHN
>A>	AB	LEADING	150MG	A215876	001	Feb 27, 2023	Feb NEWA
>A>	AB		200MG	A215876	002	Feb 27, 2023	Feb NEWA
>A>	AB		250MG	A215876	003	Feb 27, 2023	Feb NEWA
>A>	AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Feb CAHN
>A>	AB		200MG	A215315	002	Aug 26, 2022	Feb CAHN
>A>	AB		250MG	A215315	003	Aug 26, 2022	Feb CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan CAHN
+		25MG	N022256	002	Jan 14, 2009	Jan CAHN
+	!	50MG	N022256	003	Jan 14, 2009	Jan CAHN
+		100MG	N022256	004	Jan 14, 2009	Jan CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	SHANDONG	EQ 1MG BASE/ML	A216373	001	Jan 23, 2023	Jan NEWA
----	----------	----------------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB	PRASCO	7.5MG	A216751	001	Jan 18, 2023	Jan NEWA
AB		15MG	A216751	002	Jan 18, 2023	Jan NEWA
AB		30MG	A216751	003	Jan 18, 2023	Jan NEWA
AB		45MG	A216751	004	Jan 18, 2023	Jan NEWA

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

>D>	BX	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Feb DISC
>A>	@		0.1MG	A091667	001	Jul 25, 2012	Feb DISC
>D>	BX		0.2MG	A091667	002	Jul 25, 2012	Feb DISC
>A>	@		0.2MG	A091667	002	Jul 25, 2012	Feb DISC

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	CHARTWELL MOLECULAR	EQ 4MG BASE	A207464	001	Dec 06, 2018	Jan CAHN
AB		EQ 5MG BASE	A207464	002	Dec 06, 2018	Jan CAHN

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

AP	HIKMA	2MG/ML	A211452	001	Jan 12, 2023	Jan NFTG	
AP		4MG/ML	A211452	002	Jan 12, 2023	Jan NEWA	
AP		8MG/ML	A211452	003	Jan 12, 2023	Jan NEWA	
AP		10MG/ML	A211452	004	Jan 12, 2023	Jan NEWA	
		15MG/ML	A211452	005	Jan 12, 2023	Jan NFTG	
AP	+	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Jan CFTG

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

@ AKORN EQ 0.5% BASE

A202916 001 Nov 09, 2017 Jan DISC

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

&gt;A&gt; AB HETERO LABS LTD V EQ 400MG BASE

A204836 001 Mar 02, 2023 Feb NEWA

&gt;D&gt; AB TORRENT EQ 400MG BASE

A200160 001 Apr 03, 2014 Feb DISC

&gt;A&gt; @ EQ 400MG BASE

A200160 001 Apr 03, 2014 Feb DISC

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP ! EUGIA PHARMA SPECLTS EQ 1GM BASE/VIAL

A091613 001 Dec 26, 2012 Jan CHRS

AP ! EQ 2GM BASE/VIAL

A091613 002 Dec 26, 2012 Jan CHRS

AP ! EQ 10GM BASE/VIAL

A091614 001 Dec 26, 2012 Jan CHRS

@ SANDOZ EQ 1GM BASE/VIAL

A062527 002 Aug 02, 1984 Jan DISC

@ EQ 1GM BASE/VIAL

A062732 001 Dec 23, 1986 Jan DISC

@ EQ 2GM BASE/VIAL

A062527 003 Aug 02, 1984 Jan DISC

@ EQ 2GM BASE/VIAL

A062732 002 Dec 23, 1986 Jan DISC

@ EQ 10GM BASE/VIAL

A062527 004 Aug 02, 1984 Jan DISC

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

&gt;A&gt; AB AMNEAL 2%

A206960 001 Apr 10, 2017 Feb CAHN

&gt;D&gt; AB TOLMAR 2%

A206960 001 Apr 10, 2017 Feb CAHN

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

&gt;A&gt; AB AMNEAL 1%

A206165 001 Mar 20, 2019 Feb CAHN

&gt;D&gt; AB TOLMAR 1%

A206165 001 Mar 20, 2019 Feb CAHN

NAFTIN

&gt;D&gt; AB +! SEBELA IRELAND LTD 2%

N204286 001 Jun 27, 2013 Feb CTEC

&gt;A&gt; +! 2%

N204286 001 Jun 27, 2013 Feb CTEC

NALOXEGOL OXALATE

TABLET;ORAL

MOVANTIK

&gt;D&gt; + REDHILL EQ 12.5MG BASE

N204760 001 Sep 16, 2014 Feb CAHN

&gt;D&gt; +! EQ 25MG BASE

N204760 002 Sep 16, 2014 Feb CAHN

&gt;A&gt; + VALINOR EQ 12.5MG BASE

N204760 001 Sep 16, 2014 Feb CAHN

&gt;A&gt; +! EQ 25MG BASE

N204760 002 Sep 16, 2014 Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

@ PAR STERILE PRODUCTS 1MG/ML

A215964 001 Jul 29, 2022 Jan DISC

NELARABINE

INJECTABLE;INTRAVENOUS

NELARABINE

&gt;A&gt; AP SHORLA 250MG/50ML (5MG/ML)

A214809 001 Mar 03, 2023 Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

&gt;A&gt; AP SAGENT PHARMS INC 5MG/10ML (0.5MG/ML)

A216542 001 Feb 17, 2023 Feb NEWA

&gt;A&gt; AP 10MG/10ML (1MG/ML)

A216542 002 Feb 17, 2023 Feb NEWA

NITRIC OXIDE

GAS;INHALATION

GENOSYL

+! VERO BIOTECH INC 800PPM

N202860 001 Dec 20, 2019 Jan CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@ ALVOGEN 75MG;25MG

A215002 001 Jul 20, 2022 Jan DISC

OLANZAPINETABLET; ORAL  
OLANZAPINE

>A>	AB	CADILA PHARMS LTD	2.5MG	A210022	001	Feb 24, 2023	Feb NEWA
>A>	AB		5MG	A210022	002	Feb 24, 2023	Feb NEWA
>A>	AB		7.5MG	A210022	003	Feb 24, 2023	Feb NEWA
>A>	AB		10MG	A210022	004	Feb 24, 2023	Feb NEWA
>A>	AB		15MG	A210022	005	Feb 24, 2023	Feb NEWA
>A>	AB		20MG	A210022	006	Feb 24, 2023	Feb NEWA

OLMESARTAN MEDOXOMILTABLET; ORAL  
OLMESARTAN MEDOXOMIL

AB	MSN	5MG	A217399	001	Jan 18, 2023	Jan NEWA
AB		20MG	A217399	002	Jan 18, 2023	Jan NEWA
AB		40MG	A217399	003	Jan 18, 2023	Jan NEWA

>A> OMAVELOXOLONE>A> CAPSULE; ORAL  
>A> SKYCLARYS

>A>	+!	REATA PHARMS	50MG	N216718	001	Feb 28, 2023	Feb NEWA
-----	----	--------------	------	---------	-----	--------------	----------

ONDANSETRON HYDROCHLORIDETABLET; ORAL  
ONDANSETRON HYDROCHLORIDE

>D>	AB	!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007	Feb CTEC
>A>		!		EQ 24MG BASE	A077303	004	Jun 25, 2007	Feb CTEC

ORPHENADRINE CITRATETABLET, EXTENDED RELEASE; ORAL  
ORPHENADRINE CITRATE

AB	RISING	100MG	A040249	001	Jan 29, 1999	Jan CAHN
----	--------	-------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATECAPSULE; ORAL  
OSELTAMIVIR PHOSPHATE

>D>	AB		ACCORD HLTHCARE	EQ 30MG BASE	A214726	001	Jul 25, 2022	Feb DISC
>A>		@		EQ 30MG BASE	A214726	001	Jul 25, 2022	Feb DISC
>D>	AB			EQ 45MG BASE	A214726	002	Jul 25, 2022	Feb DISC
>A>		@		EQ 45MG BASE	A214726	002	Jul 25, 2022	Feb DISC
>D>	AB			EQ 75MG BASE	A214726	003	Jul 25, 2022	Feb DISC
>A>		@		EQ 75MG BASE	A214726	003	Jul 25, 2022	Feb DISC

FOR SUSPENSION; ORAL  
OSELTAMIVIR PHOSPHATE

>A>	AB		EPIC PHARMA LLC	EQ 6MG BASE/ML	A215538	001	Feb 14, 2023	Feb NEWA
-----	----	--	-----------------	----------------	---------	-----	--------------	----------

OXANDROLONETABLET; ORAL  
OXANDROLONE

>D>	AB		PAR PHARM	2.5MG	A077827	001	Jun 22, 2007	Feb DISC
>A>		@		2.5MG	A077827	001	Jun 22, 2007	Feb DISC
>D>	AB	!		10MG	A077827	002	Jun 22, 2007	Feb DISC
>A>		@		10MG	A077827	002	Jun 22, 2007	Feb DISC
>D>	AB		UPSHER SMITH LABS	2.5MG	A076761	001	Dec 01, 2006	Feb DISC
>A>		@		2.5MG	A076761	001	Dec 01, 2006	Feb DISC
>D>	AB			10MG	A078033	001	Mar 22, 2007	Feb DISC
>A>		@		10MG	A078033	001	Mar 22, 2007	Feb DISC

OXYBUTYNIN CHLORIDETABLET; ORAL  
OXYBUTYNIN CHLORIDE

!	APPCO	2.5MG	A209025	002	Feb 07, 2023	Jan NFTG
---	-------	-------	---------	-----	--------------	----------

PACLITAXELINJECTABLE; INJECTION  
PACLITAXEL

>A>	@	DASH PHARMS	6MG/ML	A091540	001	Sep 29, 2011	Feb CAHN
>D>	@	MYLAN LABS LTD	6MG/ML	A091540	001	Sep 29, 2011	Feb CAHN

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS  
PALONOSETRON HYDROCHLORIDE

>D>	AP	CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb	DISC
>A>	@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb	DISC
>D>	AP	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb	DISC
>A>	@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb	DISC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL  
PANTOPRAZOLE SODIUM

>A>	AB	AJANTA PHARMA LTD	EQ 40MG BASE	A217416	001	Feb 09, 2023	Feb	NEWA
-----	----	-------------------	--------------	---------	-----	--------------	-----	------

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
PAROXETINE HYDROCHLORIDE

@	EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan	CAHN
@		EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan	CAHN
@		EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan	CAHN

PEGCETACOPLAN

>A>		SOLUTION; INTRAVITREAL						
>A>		SYFOVRE						
>A>	+	APPELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023	Feb	NEWA

PEMETREXED DISODIUM

POWDER; INTRAVENOUS  
PEMETREXED DISODIUM

AP		MEITHEAL	EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan	CAHN
AP			EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan	CAHN
AP			EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan	CAHN
		SOLUTION; INTRAVENOUS						
		PEMETREXED DISODIUM						
	+	SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan	CMS1

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION  
PENTAMIDINE ISETHIONATE

AN		X-GEN PHARMS INC	300MG/VIAL	A206983	001	Jan 20, 2023	Jan	NEWA
----	--	------------------	------------	---------	-----	--------------	-----	------

PERAMPANEL

SUSPENSION; ORAL  
FYCOMPA

>A>	+	CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Feb	CAHN
>D>	+	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016	Feb	CAHN
		TABLET; ORAL						
		FYCOMPA						
>A>	+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	Feb	CAHN
>A>	+		4MG	N202834	002	Oct 22, 2012	Feb	CAHN
>A>	+		6MG	N202834	003	Oct 22, 2012	Feb	CAHN
>A>	+		8MG	N202834	004	Oct 22, 2012	Feb	CAHN
>A>	+		10MG	N202834	005	Oct 22, 2012	Feb	CAHN
>A>	+		12MG	N202834	006	Oct 22, 2012	Feb	CAHN
>D>	+	EISAI INC	2MG	N202834	001	Oct 22, 2012	Feb	CAHN
>D>	+		4MG	N202834	002	Oct 22, 2012	Feb	CAHN
>D>	+		6MG	N202834	003	Oct 22, 2012	Feb	CAHN
>D>	+		8MG	N202834	004	Oct 22, 2012	Feb	CAHN
>D>	+		10MG	N202834	005	Oct 22, 2012	Feb	CAHN
>D>	+		12MG	N202834	006	Oct 22, 2012	Feb	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL  
PHENTERMINE HYDROCHLORIDE

>D>	AA	LANNETT	15MG	A087022	002	Jan 20, 2012	Feb	DISC
>A>	@		15MG	A087022	002	Jan 20, 2012	Feb	DISC
>D>	AA		30MG	A087022	001	Feb 03, 1983	Feb	DISC

		CAPSULE;ORAL							
		PHENTERMINE HYDROCHLORIDE							
>A>	@	30MG		A087022	001	Feb 03, 1983		Feb	DISC
		<u>PHENYLEPHRINE HYDROCHLORIDE</u>							
		SOLUTION;INTRAVENOUS							
		PHENYLEPHRINE HYDROCHLORIDE							
>A>	AP2	AVET LIFESCIENCES	10MG/ML (10MG/ML)	A209968	001	Feb 28, 2023		Feb	NEWA
		<u>PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>							
		SYRUP;ORAL							
		PROMETHAZINE VC PLAIN							
	@	XTTRIUM LABS INC	5MG/5ML;6.25MG/5ML	A088897	001	Jan 04, 1985		Jan	CAHN
		<u>PHYTONADIONE</u>							
		TABLET;ORAL							
		MEPHYTON							
>D>	AB	+!	BAUSCH	5MG	N010104	003		Feb	DISC
>A>		+	@	5MG	N010104	003		Feb	DISC
		PHYTONADIONE							
>D>	AB		ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb	CHRS
>A>	AB	!		5MG	A210189	001	Feb 20, 2019	Feb	CHRS
		<u>PIRTOBRUTINIB</u>							
		TABLET;ORAL							
		JAYPIRCA							
	+	LOXO ONCOL	50MG	N216059	001	Jan 27, 2023		Jan	NEWA
	+	!	100MG	N216059	002	Jan 27, 2023		Jan	NEWA
		<u>PITAVASTATIN CALCIUM</u>							
		TABLET;ORAL							
		PITAVASTATIN CALCIUM							
>A>	AB		ZYDUS PHARMS	EQ 1MG BASE	A206047	001	Feb 22, 2023	Feb	NEWA
>A>	AB			EQ 2MG BASE	A206047	002	Feb 22, 2023	Feb	NEWA
>A>	AB			EQ 4MG BASE	A206047	003	Feb 22, 2023	Feb	NEWA
		<u>POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE</u>							
		SOLUTION/DROPS;OPHTHALMIC							
		POLYTRIM							
>D>	AT	+	! ALLERGAN	10,000 UNITS/ML;EQ 1MG BASE/ML	N050567	001	Oct 20, 1988	Feb	DISC
>A>		+	@	10,000 UNITS/ML;EQ 1MG BASE/ML	N050567	001	Oct 20, 1988	Feb	DISC
		TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE							
>D>	AT		SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CHRS
>A>	AT	!		10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CHRS
		<u>POMALIDOMIDE</u>							
		CAPSULE;ORAL							
		POMALYST							
	+	BRISTOL	1MG	N204026	001	Feb 08, 2013		Jan	CAHN
	+		2MG	N204026	002	Feb 08, 2013		Jan	CAHN
	+		3MG	N204026	003	Feb 08, 2013		Jan	CAHN
	+	!	4MG	N204026	004	Feb 08, 2013		Jan	CAHN
		<u>POTASSIUM ACETATE</u>							
		INJECTABLE;INJECTION							
		POTASSIUM ACETATE							
>D>	@	EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021		Feb	CMFD
>A>	AP		2MEQ/ML	A212692	001	Oct 20, 2021		Feb	CMFD
		<u>POTASSIUM CHLORIDE</u>							
		SOLUTION;ORAL							
		POTASSIUM CHLORIDE							
>A>	AA		BELCHER	20MEQ/15ML	A216156	001	Mar 07, 2023	Feb	NEWA
>A>	AA			40MEQ/15ML	A216156	002	Mar 07, 2023	Feb	NEWA
		TABLET, EXTENDED RELEASE;ORAL							
		K-TAB							
>D>	AB3	+	ABBVIE	10MEQ	N018279	001		Feb	DISC
>A>		+	@	10MEQ	N018279	001		Feb	DISC
>D>	AB3	+	!	20MEQ	N018279	003	Nov 25, 2013	Feb	DISC
>A>		+	@	20MEQ	N018279	003	Nov 25, 2013	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

>D> AB3 VITRUVIAS THERAP 20MEQ A209688 002 Jan 12, 2018 Feb CHRS  
>A> AB3 ! 20MEQ A209688 002 Jan 12, 2018 Feb CHRS

PRASUGREL

TABLET;ORAL  
PRASUGREL HYDROCHLORIDE

>D> AB LUPIN LTD EQ 5MG BASE A205930 001 Jan 09, 2023 Feb DISC  
>D> AB EQ 10MG BASE A205930 002 Jan 09, 2023 Feb DISC

PRASUGREL HYDROCHLORIDE

TABLET;ORAL  
PRASUGREL

>A> @ LUPIN LTD EQ 5MG BASE A205930 001 Jan 09, 2023 Feb DISC  
>A> @ EQ 10MG BASE A205930 002 Jan 09, 2023 Feb DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL  
PRAZOSIN HYDROCHLORIDE

>A> AB ALEMBIC EQ 1MG BASE A217268 001 Mar 06, 2023 Feb NEWA  
>A> AB EQ 2MG BASE A217268 002 Mar 06, 2023 Feb NEWA  
>A> AB EQ 5MG BASE A217268 003 Mar 06, 2023 Feb NEWA

PREDNISOLONE

SYRUP;ORAL  
PREDNISOLONE

AA XTTRIUM LABS INC 15MG/5ML A040313 001 Sep 10, 2003 Jan CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC  
PRED FORTE

AB +! ABBVIE 1% N017011 001 Jan CAHN

PRED MILD

>A> +! ABBVIE 0.12% N017100 001 Feb CAHN  
>D> +! ALLERGAN 0.12% N017100 001 Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL  
PREDNISOLONE SODIUM PHOSPHATE

AA EDENBRIDGE PHARMS EQ 15MG BASE/5ML A203559 003 Feb 06, 2023 Jan NEWA  
AA EQ 15MG BASE/5ML A203559 003 Feb 06, 2023 Jan NEWA  
AA EQ 25MG BASE/5ML A203559 004 Feb 06, 2023 Jan NEWA  
AA EQ 25MG BASE/5ML A203559 004 Feb 06, 2023 Jan NEWA  
AA ! MISSION PHARMA EQ 25MG BASE/5ML A091396 001 Sep 13, 2010 Jan CTEC  
AA XTTRIUM LABS INC EQ 5MG BASE/5ML A075099 001 Jun 28, 2002 Jan CAHN  
AA ! EQ 15MG BASE/5ML A076895 001 Oct 04, 2004 Jan CAHN

PREDNISON

SOLUTION;ORAL  
PREDNISON

@ XTTRIUM LABS INC 5MG/5ML A089726 001 Aug 02, 1988 Jan CAHN

TABLET;ORAL  
PREDNISON

AB +! HIKMA 2.5MG A087801 001 Apr 22, 1982 Jan CRLD  
AB +! 5MG A080352 001 Jan CRLD  
AB +! 50MG A084283 001 Jan CRLD

PREGABALIN

SOLUTION;ORAL  
PREGABALIN

AA PATRIN 20MG/ML A212604 001 Feb 18, 2022 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL  
PREGABALIN

@ ZYDUS PHARMS 82.5MG A215577 001 Aug 26, 2022 Jan DISC  
@ 165MG A215577 002 Aug 26, 2022 Jan DISC  
@ 330MG A215577 003 Aug 26, 2022 Jan DISC



PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
PROCAINAMIDE HYDROCHLORIDE

>D>	!	HOSPIRA	500MG/ML	A 089070	001	Feb 12, 1986	Feb CTEC
>A>	AP	!	500MG/ML	A 089070	001	Feb 12, 1986	Feb CTEC

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
PROPAFENONE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	225MG	A 213096	001	Feb 21, 2023	Feb NEWA
>A>	AB		325MG	A 213096	002	Feb 21, 2023	Feb NEWA
>A>	AB		425MG	A 213096	003	Feb 21, 2023	Feb NEWA

PROPOFOL

INJECTABLE; INJECTION  
PROPOFOL

AB		AVET LIFESCIENCES	10MG/ML	A 206408	001	Oct 12, 2021	Jan CAHN
----	--	-------------------	---------	----------	-----	--------------	----------

RAMELTEON

TABLET; ORAL  
RAMELTEON

AB		INNOGENIX	8MG	A 215435	001	Aug 24, 2022	Jan CAHN
>A>	AB	MICRO LABS	8MG	A 215243	001	Feb 09, 2023	Feb NEWA

RAMIPRIL

CAPSULE; ORAL  
RAMIPRIL

>D>	AB	APOTEX	1.25MG	A 079116	001	Jun 20, 2008	Feb CAHN
>D>	AB		2.5MG	A 079116	002	Jun 20, 2008	Feb CAHN
>D>	AB		5MG	A 079116	003	Jun 20, 2008	Feb CAHN
>D>	AB		10MG	A 079116	004	Jun 20, 2008	Feb CAHN
>A>	AB	COREPHARMA	1.25MG	A 079116	001	Jun 20, 2008	Feb CAHN
>A>	AB		2.5MG	A 079116	002	Jun 20, 2008	Feb CAHN
>A>	AB		5MG	A 079116	003	Jun 20, 2008	Feb CAHN
>A>	AB		10MG	A 079116	004	Jun 20, 2008	Feb CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL  
RANEXA

+	@	GILEAD	500MG	N 021526	002	Jan 27, 2006	Jan DISC
+	@		1GM	N 021526	001	Feb 12, 2007	Jan DISC
AB	!	SUN PHARM	1GM	A 211707	002	May 28, 2019	Jan CHRS

REGADENOSON

SOLUTION; INTRAVENOUS  
REGADENOSON

AP		HIKMA	0.4MG/5ML (0.08MG/ML)	A 215827	001	Feb 02, 2023	Jan NEWA
----	--	-------	-----------------------	----------	-----	--------------	----------

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING; ORAL  
NURTEC ODT

>D>	+	BIOHAVEN IRELAND	EQ 75MG BASE	N 212728	001	Feb 27, 2020	Feb CAHN
>A>	+	PFIZER	EQ 75MG BASE	N 212728	001	Feb 27, 2020	Feb CAHN

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
RYKINDO

+	!	SHANDONG LUYE	12.5MG	N 212849	001	Jan 13, 2023	Jan NEWA
+	!		25MG	N 212849	002	Jan 13, 2023	Jan NEWA
+	!		37.5MG	N 212849	003	Jan 13, 2023	Jan NEWA
+	!		50MG	N 212849	004	Jan 13, 2023	Jan NEWA

TABLET; ORAL

RISPERIDONE

>A>	@	DASH PHARMS	0.25MG	A 076288	001	Sep 15, 2008	Feb CAHN
>A>	@		0.5MG	A 076288	002	Sep 15, 2008	Feb CAHN
>A>	@		1MG	A 076288	003	Sep 15, 2008	Feb CAHN
>A>	@		2MG	A 076288	004	Sep 15, 2008	Feb CAHN
>A>	@		3MG	A 076288	005	Sep 15, 2008	Feb CAHN
>A>	@		4MG	A 076288	006	Sep 15, 2008	Feb CAHN
>D>	@	MYLAN	0.25MG	A 076288	001	Sep 15, 2008	Feb CAHN

TABLET;ORAL							
RISPERIDONE							
>D>	@	0.5MG	A076288	002	Sep 15, 2008	Feb	CAHN
>D>	@	1MG	A076288	003	Sep 15, 2008	Feb	CAHN
>D>	@	2MG	A076288	004	Sep 15, 2008	Feb	CAHN
>D>	@	3MG	A076288	005	Sep 15, 2008	Feb	CAHN
>D>	@	4MG	A076288	006	Sep 15, 2008	Feb	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
RISPERIDONE							
>A>	@ DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013	Feb	CAHN
>A>	@	0.5MG	A091537	001	Mar 30, 2011	Feb	CAHN
>A>	@	1MG	A091537	002	Mar 30, 2011	Feb	CAHN
>A>	@	2MG	A091537	003	Mar 30, 2011	Feb	CAHN
>A>	@	3MG	A091537	004	Mar 30, 2011	Feb	CAHN
>A>	@	4MG	A091537	005	Mar 30, 2011	Feb	CAHN
>D>	@ MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Feb	CAHN
>D>	@	0.5MG	A091537	001	Mar 30, 2011	Feb	CAHN
>D>	@	1MG	A091537	002	Mar 30, 2011	Feb	CAHN
>D>	@	2MG	A091537	003	Mar 30, 2011	Feb	CAHN
>D>	@	3MG	A091537	004	Mar 30, 2011	Feb	CAHN
>D>	@	4MG	A091537	005	Mar 30, 2011	Feb	CAHN
>D>	<u>RITONAVIR</u>						
>D>	SOLUTION;ORAL						
>D>	NORVIR						
>D>	+! ABBVIE	80MG/ML	N020659	001	Mar 01, 1996	Feb	DISC
>A>	+ @	80MG/ML	N020659	001	Mar 01, 1996	Feb	DISC
>D>	<u>ROCURONIUM BROMIDE</u>						
>D>	INJECTABLE;INJECTION						
>D>	ROCURONIUM BROMIDE						
>A> AP	CAPLIN	50MG/5ML (10MG/ML)	A216234	001	Mar 02, 2023	Feb	NEWA
>A> AP		100MG/10ML (10MG/ML)	A216234	002	Mar 02, 2023	Feb	NEWA
>D>	<u>ROPIVACAINE HYDROCHLORIDE</u>						
>D>	SOLUTION;INJECTION						
>D>	ROPIVACAINE HYDROCHLORIDE						
>A> AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb	NEWA
>A> AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb	NEWA
>A> AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb	NEWA
>A> AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb	NEWA
>D>	<u>SEVELAMER CARBONATE</u>						
>D>	FOR SUSPENSION;ORAL						
>D>	SEVELAMER CARBONATE						
>A> AB	HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Feb	NEWA
>A> AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb	NEWA
>D>	<u>SIROLIMUS</u>						
>D>	SOLUTION;ORAL						
>D>	SIROLIMUS						
AA	MSN	1MG/ML	A216728	001	Jan 19, 2023	Jan	NEWA
>D>	TABLET;ORAL						
>D>	SIROLIMUS						
>A> AB	ZYDUS PHARMS	1MG	A201676	001	Feb 15, 2023	Feb	NEWA
>A> AB		2MG	A201676	002	Feb 15, 2023	Feb	NEWA
>D>	<u>SODIUM PHENYLBUTYRATE</u>						
>D>	POWDER;ORAL						
>D>	BUPHENYL						
AB	+! HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan	CAHN
>D>	TABLET;ORAL						
>D>	BUPHENYL						
AB	+! HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan	CAHN
>D>	<u>SOTORASIB</u>						
>D>	TABLET;ORAL						
>D>	LUMAKRAS						
>A>	+ AMGEN INC	320MG	N214665	002	Jan 20, 2023	Feb	NEWA

>A>	<u>SPARSENTAN</u>							
>A>	TABLET;ORAL							
>A>	FILSPARI							
>A>	+	TRAVERE	200MG	N216403	001	Feb 17, 2023	Feb	NEWA
>A>	+	!	400MG	N216403	002	Feb 17, 2023	Feb	NEWA
	<u>STERILE WATER FOR INJECTION</u>							
	LIQUID;N/A							
	STERILE WATER FOR INJECTION							
AP	HIKMA		100%	A212735	001	Jan 31, 2023	Jan	NEWA
	<u>SUCCINYLCHOLINE CHLORIDE</u>							
	INJECTABLE;INJECTION							
	SUCCINYLCHOLINE CHLORIDE							
AP	MANKIND PHARMA		20MG/ML	A216127	001	Feb 02, 2023	Jan	NEWA
	<u>SULFACETAMIDE SODIUM</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	SULFACETAMIDE SODIUM							
	@	AKORN	10%	A040215	001	May 25, 1999	Jan	DISC
	<u>SULINDAC</u>							
	TABLET;ORAL							
	SULINDAC							
	@	CHARTWELL RX	150MG	A072712	001	Aug 30, 1991	Jan	CAHN
	@		200MG	A072713	001	Aug 30, 1991	Jan	CAHN
	<u>TADALAFIL</u>							
	TABLET;ORAL							
	TADALAFIL							
>A>	AB1	NOVITIUM PHARMA	5MG	A215949	001	Mar 03, 2023	Feb	NEWA
>A>	AB1		10MG	A215949	002	Mar 03, 2023	Feb	NEWA
>A>	AB1		20MG	A215949	003	Mar 03, 2023	Feb	NEWA
	AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Jan	CTEC
	AB1		5MG	A209250	002	Mar 26, 2019	Jan	CTEC
	AB1		10MG	A209250	003	Mar 26, 2019	Jan	CTEC
	AB1		20MG	A209250	004	Mar 26, 2019	Jan	CTEC
	<u>TAMOXIFEN CITRATE</u>							
	SOLUTION;ORAL							
	SOLTAMOX							
>A>	+	MAYNE PHARMA COMMRC	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Feb	CAHN
>D>	+	MAYNE PHARMA INC	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Feb	CAHN
	<u>TASIMELTEON</u>							
	CAPSULE;ORAL							
	TASIMELTEON							
AB	APOTEX		20MG	A211607	001	Dec 20, 2022	Jan	CAHN
AB	MSN		20MG	A211654	001	Jan 12, 2023	Jan	NEWA
	<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>							
	POWDER;INTRAVENOUS							
	TECHNETIUM TC 99M MERTIATIDE KIT							
	+	JUBILANT DRAXIMAGE	N/A	N216820	001	Jan 30, 2023	Jan	NEWA
	<u>TENOFOVIR DISOPROXIL FUMARATE</u>							
	TABLET;ORAL							
	TENOFOVIR DISOPROXIL FUMARATE							
>A>	AB	REYOUNG PHARM	300MG	A211337	001	Mar 02, 2023	Feb	NEWA
	<u>TERIFLUNOMIDE</u>							
	TABLET;ORAL							
	TERIFLUNOMIDE							
>D>	@	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb	CMFD
>A>	AB		7MG	A209613	001	Sep 28, 2018	Feb	CMFD
>D>	@		14MG	A209613	002	Sep 28, 2018	Feb	CMFD
>A>	AB		14MG	A209613	002	Sep 28, 2018	Feb	CMFD
	AB	APOTEX	7MG	A209601	001	Nov 02, 2018	Jan	CMFD
	AB		14MG	A209601	002	Nov 02, 2018	Jan	CMFD
	AB	AUROBINDO PHARMA	7MG	A209638	001	Oct 26, 2018	Jan	CMFD
	AB		14MG	A209638	002	Oct 26, 2018	Jan	CMFD

TABLET;ORAL

TERIFLUNOMIDE

>D>	@ MSN	7MG	A209623	001	Apr 24, 2019	Feb	CMFD	
>A>	AB	7MG	A209623	001	Apr 24, 2019	Feb	CMFD	
>D>	@	14MG	A209623	002	Apr 24, 2019	Feb	CMFD	
>A>	AB	14MG	A209623	002	Apr 24, 2019	Feb	CMFD	
>D>	@ MYLAN	7MG	A209702	001	Feb 28, 2020	Feb	CMFD	
>A>	AB	7MG	A209702	001	Feb 28, 2020	Feb	CMFD	
>D>	@	14MG	A209702	002	Feb 28, 2020	Feb	CMFD	
>A>	AB	14MG	A209702	002	Feb 28, 2020	Feb	CMFD	
>D>	@ SOLA PHARMS	14MG	A209677	001	Jun 17, 2020	Feb	CMFD	
>A>	AB	14MG	A209677	001	Jun 17, 2020	Feb	CMFD	
>D>	@ TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Feb	CMFD	
>A>	AB	7MG	A209700	001	Sep 04, 2018	Feb	CMFD	
>D>	@	14MG	A209700	002	Sep 04, 2018	Feb	CMFD	
>A>	AB	14MG	A209700	002	Sep 04, 2018	Feb	CMFD	
	AB	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	Jan	CMFD
	AB		14MG	A209668	002	Nov 30, 2018	Jan	CMFD

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

>D>	+ @ ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Feb	CAHN
>D>	+ @	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Feb	CAHN
>D>	+ @	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Feb	CAHN
>D>	+ @	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Feb	CAHN
>A>	+ @ BESINS HLTHCARE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Feb	CAHN
>A>	+ @	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Feb	CAHN
>A>	+ @	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Feb	CAHN
>A>	+ @	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Feb	CAHN

GEL, METERED;NASAL

NATESTO

+!	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan	CHRS
+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan	CRLD

GEL, METERED;TRANSDERMAL

ANDROGEL

>D>	AB	+! ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Feb	CAHN
>D>		+ @	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Feb	CAHN
>A>	AB	+! BESINS HLTHCARE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Feb	CAHN
>A>		+ @	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Feb	CAHN

TESTOSTERONE

AB		ENCUBE	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Jan	CAHN
----	--	--------	----------------------------------	---------	-----	--------------	-----	------

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

	@ SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan	DISC
	@	25MG	A206129	002	Aug 17, 2015	Jan	DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB		LEADING	300MG	A214950	001	Jan 30, 2023	Jan	NEWA
AB			450MG	A214950	002	Jan 30, 2023	Jan	NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

>A>	AP	CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb	NEWA
-----	----	--------	----------	---------	-----	--------------	-----	------

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

	@ CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan	CAHN
	@	15MG	A088132	001	Aug 30, 1983	Jan	CAHN
	@	25MG	A088133	001	Aug 30, 1983	Jan	CAHN
	@	50MG	A088134	001	Aug 30, 1983	Jan	CAHN
	@	100MG	A088135	001	Nov 20, 1984	Jan	CAHN
	@	150MG	A088136	001	Sep 17, 1986	Jan	CAHN
	@	200MG	A088137	001	Sep 17, 1986	Jan	CAHN

THIOTHIXENECAPSULE;ORAL  
THIOTHIXENE

>D>	AB	MYLAN	1MG	A 071093	002	Jun 23, 1987	Feb	CAHN
>D>	AB		2MG	A 071093	003	Jun 23, 1987	Feb	CAHN
>D>	AB		5MG	A 071093	004	Jun 23, 1987	Feb	CAHN
>D>	AB		10MG	A 071093	001	Jun 23, 1987	Feb	CAHN
>A>	AB	RISING	1MG	A 071093	002	Jun 23, 1987	Feb	CAHN
>A>	AB		2MG	A 071093	003	Jun 23, 1987	Feb	CAHN
>A>	AB		5MG	A 071093	004	Jun 23, 1987	Feb	CAHN
>A>	AB		10MG	A 071093	001	Jun 23, 1987	Feb	CAHN

TIMOLOLSOLUTION/DROPS;OPHTHALMIC  
BETIMOL

+	!	THEA PHARMA	EQ 0.25% BASE	N 020439	001	Mar 31, 1995	Jan	CTEC
+	!		EQ 0.5% BASE	N 020439	002	Mar 31, 1995	Jan	CTEC
		TIMOLOL						
		@ AKORN	EQ 0.25% BASE	A 205309	001	Sep 30, 2016	Jan	DISC
		@	EQ 0.5% BASE	A 205309	002	Sep 30, 2016	Jan	DISC

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS;OPHTHALMIC  
TIMOLOL MALEATE

>A>	AB	GLAND PHARMA LTD	EQ 0.5% BASE	A 214645	002	Feb 14, 2023	Feb	NEWA
		SOLUTION/DROPS;OPHTHALMIC						
		TIMOLOL MALEATE						
		@ AKORN	EQ 0.5% BASE	A 074466	001	Mar 25, 1997	Jan	DISC

TIOPRONINTABLET, DELAYED RELEASE;ORAL  
THIOLA EC

>D>	+	MISSION PHARMACAL CO	100MG	N 211843	001	Jun 28, 2019	Feb	CFTG
>A>	AB	+	100MG	N 211843	001	Jun 28, 2019	Feb	CFTG
>D>	+		300MG	N 211843	002	Jun 28, 2019	Feb	CFTG
>A>	AB	+	300MG	N 211843	002	Jun 28, 2019	Feb	CFTG
		TIOPRONIN						
>A>	AB	PAR PHARM	100MG	A 217219	001	Feb 24, 2023	Feb	NFTG
>A>	AB		300MG	A 217219	002	Feb 24, 2023	Feb	NFTG

TIROFIBAN HYDROCHLORIDESOLUTION;INTRAVENOUS  
AGGRASTAT

AP	+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N 020913	002	May 17, 2002	Jan	CFTG
AP		TIROFIBAN HYDROCHLORIDE						
AP		NEXUS PHARMS	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A 213947	001	Feb 07, 2023	Jan	NFTG

TOBRAMYCINSOLUTION/DROPS;OPHTHALMIC  
AKTOB

>D>	AT	AKORN	0.3%	A 064096	001	Jan 31, 1996	Feb	DISC
>A>		@	0.3%	A 064096	001	Jan 31, 1996	Feb	DISC

TOBRAMYCIN SULFATEINJECTABLE;INJECTION  
TOBRAMYCIN SULFATE

AP		HAINAN POLY	EQ 1.2GM BASE/VIAL	A 217029	001	Feb 01, 2023	Jan	NEWA
----	--	-------------	--------------------	----------	-----	--------------	-----	------

TOPIRAMATECAPSULE, EXTENDED RELEASE;ORAL  
TOPIRAMATE

>A>	AB1	PAR PHARM	200MG	A 205976	001	Mar 01, 2023	Feb	NEWA
	AB1	ZYDUS	25MG	A 207382	001	Nov 24, 2017	Jan	CAHN
	AB2		25MG	A 208949	001	Nov 29, 2022	Jan	CAHN
	AB1		50MG	A 207382	002	Nov 24, 2017	Jan	CAHN
	AB2		50MG	A 208949	002	Nov 29, 2022	Jan	CAHN
	AB1		100MG	A 207382	003	Nov 24, 2017	Jan	CAHN
	AB2		100MG	A 208949	003	Nov 29, 2022	Jan	CAHN
	AB2		150MG	A 208949	004	Nov 29, 2022	Jan	CAHN

CAPSULE, EXTENDED RELEASE;ORAL  
TOPIRAMATE

AB2		200MG	A208949	005	Nov 29, 2022	Jan CAHN
AB1	ZYDUS PHARMS	200MG	A216167	001	Feb 09, 2023	Jan NFTG
AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan CFTG

TRAZODONE HYDROCHLORIDE

TABLET;ORAL  
TRAZODONE HYDROCHLORIDE

AB	AUROBINDO PHARMA	50MG	A204852	001	Feb 05, 2020	Jan CAHN
AB		100MG	A204852	002	Feb 05, 2020	Jan CAHN
AB		150MG	A204852	003	Feb 05, 2020	Jan CAHN
AB		300MG	A204852	004	Feb 05, 2020	Jan CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS  
TREPROSTINIL

>D>	@ DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Feb CMFD
>A>	AP	1MG/ML	A210214	001	May 22, 2020	Feb CMFD
>D>	@	2.5MG/ML	A210214	002	May 22, 2020	Feb CMFD
>A>	AP	2.5MG/ML	A210214	002	May 22, 2020	Feb CMFD
>D>	@	5MG/ML	A210214	003	May 22, 2020	Feb CMFD
>A>	AP	5MG/ML	A210214	003	May 22, 2020	Feb CMFD
>D>	@	10MG/ML	A210214	004	May 22, 2020	Feb CMFD
>A>	AP	10MG/ML	A210214	004	May 22, 2020	Feb CMFD

TRETINOIN

CREAM;TOPICAL  
RETIN-A

AB	+! BAUSCH	0.025%	N019049	001	Sep 16, 1988	Jan CAHN
----	-----------	--------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL  
TRIAMCINOLONE ACETONIDE

AT	GLASSHOUSE PHARMS	0.05%	A214532	001	Jan 27, 2023	Jan NEWA
----	-------------------	-------	---------	-----	--------------	----------

TRIAMTERENE

CAPSULE;ORAL  
TRIAMTERENE

@	EYWA	50MG	A214768	001	Jul 06, 2022	Jan DISC
@		100MG	A214768	002	Jul 06, 2022	Jan DISC

UBROGEPANT

TABLET;ORAL  
UBRELVY

+	ABBVIE	50MG	N211765	001	Dec 23, 2019	Jan CAHN
+!		100MG	N211765	002	Dec 23, 2019	Jan CAHN

URSODIOL

CAPSULE;ORAL  
URSODIOL

@	MYLAN	300MG	A090530	001	Feb 17, 2010	Jan DISC
---	-------	-------	---------	-----	--------------	----------

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL  
VALACYCLOVIR HYDROCHLORIDE

AB	CHARTWELL RX	EQ 500MG BASE	A090216	001	May 24, 2010	Jan CAHN
AB		EQ 1GM BASE	A090216	002	May 24, 2010	Jan CAHN

VALSARTAN

SOLUTION;ORAL  
VALSARTAN

!	NOVITIUM PHARMA	20MG/5ML	A214102	001	Nov 02, 2021	Jan CHRS
---	-----------------	----------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION  
VANCOMYCIN HYDROCHLORIDE

AP	HIKMA	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jan CMFD
----	-------	------------------	---------	-----	--------------	----------

POWDER; INTRAVENOUS, ORAL  
VANCOMYCIN HYDROCHLORIDE

+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan NEWA
+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan NEWA
+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan NEWA
+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan NEWA

VARENICLINE TARTRATE

TABLET; ORAL  
VARENICLINE TARTRATE

AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan NEWA
AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan NEWA
AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan CTEC

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL  
VENLAFAXINE HYDROCHLORIDE

@	CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN

VIGABATRIN

FOR SOLUTION; ORAL  
VIGABATRIN

>A>	AA	ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Feb NEWA
-----	----	-------	--------------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL  
VILIBRYD

AB	+!	ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan CAHN
AB	+		20MG	N022567	002	Jan 21, 2011	Jan CAHN
AB	+		40MG	N022567	003	Jan 21, 2011	Jan CAHN

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
VORICONAZOLE

AP		EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Jan NEWA
----	--	--------------	------------	---------	-----	--------------	----------

VUTRISIRAN

SOLUTION; SUBCUTANEOUS  
AMVUTTRA

>D>	+!	ALNYLAM PHARMS INC	25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
-----	----	--------------------	-------------------------	---------	-----	--------------	----------

VUTRISIRAN SODIUM

SOLUTION; SUBCUTANEOUS  
AMVUTTRA

>A>	+!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
-----	----	--------------------	---	---------	-----	--------------	----------

XENON XE-129 HYPERPOLARIZED

GAS; INHALATION  
XENOVIEW

+!	POLAREAN	N/A	N214375	001	Dec 23, 2022	Jan NEWA
----	----------	-----	---------	-----	--------------	----------

ZILEUTON

TABLET, EXTENDED RELEASE; ORAL  
ZILEUTON

AB	!	LUPIN LTD	600MG	A211972	001	Nov 05, 2019	Jan DISC
		RISING	600MG	A204929	001	Mar 17, 2017	Jan CHRS
		ZYFLO CR					
	+	@ CHIESI	600MG	N022052	001	May 30, 2007	Jan DISC

ZOLMITRIPTAN

SPRAY; NASAL  
ZOMIG

AB	+	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Jan CAHN
AB	+!		5MG/SPRAY	N021450	004	Sep 30, 2003	Jan CAHN

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ACETAMINOPHEN AND IBUPROFEN

>A>	L PERRIGO CO	250MG;125MG	A214836	001	Feb 28, 2023	Feb	NEWA
-----	--------------	-------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	AUROBINDO PHARMA LTD	5MG;120MG	A212409	001	Mar 08, 2023	Feb	NEWA
-----	----------------------	-----------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

>D>	APOTEX	25MG;220MG	A211830	001	Aug 22, 2019	Feb	CAHN
-----	--------	------------	---------	-----	--------------	-----	------

>A>	COREPHARMA	25MG;220MG	A211830	001	Aug 22, 2019	Feb	CAHN
-----	------------	------------	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>A>	MARKSANS PHARMA	10MG	A217543	001	Mar 08, 2023	Feb	NEWA
-----	-----------------	------	---------	-----	--------------	-----	------

>A>		20MG	A217543	002	Mar 08, 2023	Feb	NEWA
-----	--	------	---------	-----	--------------	-----	------

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	GRANULES	600MG;60MG	A216082	001	Aug 22, 2022	Feb	DISC
-----	----------	------------	---------	-----	--------------	-----	------

>A>	@	600MG;60MG	A216082	001	Aug 22, 2022	Feb	DISC
-----	---	------------	---------	-----	--------------	-----	------

>D>		1.2GM;120MG	A216082	002	Aug 22, 2022	Feb	DISC
-----	--	-------------	---------	-----	--------------	-----	------

>A>	@	1.2GM;120MG	A216082	002	Aug 22, 2022	Feb	DISC
-----	---	-------------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

>D>	GRANULES	2MG;125MG	A215981	001	Aug 29, 2022	Feb	DISC
-----	----------	-----------	---------	-----	--------------	-----	------

>A>	@	2MG;125MG	A215981	001	Aug 29, 2022	Feb	DISC
-----	---	-----------	---------	-----	--------------	-----	------

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

>D>	STRIDES PHARMA	EQ 200MG BASE	A215472	001	Aug 17, 2022	Feb	DISC
-----	----------------	---------------	---------	-----	--------------	-----	------

>A>	@	EQ 200MG BASE	A215472	001	Aug 17, 2022	Feb	DISC
-----	---	---------------	---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ AKORN EQ 0.1% BASE

A204532 001 Jan 10, 2017 Jan DISC

@ EQ 0.2% BASE

A204723 001 Dec 05, 2017 Jan DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

APOTEX 0.055MG/SPRAY

A214615 001 Jan 19, 2023 Jan NEWA



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2023**

NO FEBRUARY 2023 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001					NCE	Dec 12, 2027
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
<u>ALPELISIB - VIJOICE</u>						
N 215039 001					ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 002					ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 003					ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11540981	Feb 07, 2028	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR</u>						
N 208147 001	>A> 11590228	Sep 07, 2036	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5</u>						
N 210526 001	>A> 11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10</u>						
N 210526 002	>A> 11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15</u>						
N 210526 003	>A> 11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20</u>						
N 210526 004	>A> 11590081	Sep 24, 2038	DP U-3538			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	11559559	Dec 18, 2034	U-3514			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	10052314	Sep 23, 2033	U-2381		Y	
	10052314	Sep 23, 2033	U-2382		Y	
	>A> 9481663	Jun 04, 2033	DS DP U-2237			
	>A> 9481663	Jun 04, 2033	DS DP U-2624			
	RE49353	Sep 23, 2033	U-2381			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	>A> 10702508	Apr 30, 2038	U-3012			
	>A> 10849888	Sep 23, 2033	U-3013			
	>A> 8445507	Sep 15, 2030	DS DP U-2237			
	>A> 8445507	Sep 15, 2030	DS DP U-2624			
	>A> 8802689	Mar 27, 2027	U-2237			
	>A> 8802689	Mar 27, 2027	U-2624			
	>A> 9388159	Mar 27, 2027	DS DP			
	>A> 9481663	Jun 04, 2033	DS DP U-2237			
	>A> 9481663	Jun 04, 2033	DS DP U-2624			
	>A> 9884054	Sep 23, 2033	U-2237			
	>A> 9987261	Mar 27, 2027	DP			
	>A> RE49353	Sep 23, 2033	U-2381			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	>A> 10702508	Apr 30, 2038	U-3012			
	>A> 10849888	Sep 23, 2033	U-3013			
	>A> 8445507	Sep 15, 2030	DS DP U-2237			
	>A> 8445507	Sep 15, 2030	DS DP U-2624			
	>A> 8802689	Mar 27, 2027	U-2237			
	>A> 8802689	Mar 27, 2027	U-2624			
	>A> 9388159	Mar 27, 2027	DS DP			
	>A> 9481663	Jun 04, 2033	DS DP U-2237			
	>A> 9481663	Jun 04, 2033	DS DP U-2624			
	>A> 9884054	Sep 23, 2033	U-2237			
	>A> 9987261	Mar 27, 2027	DP			
	>A> RE49353	Sep 23, 2033	U-2381			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	>A> 11369567	Jun 07, 2037	DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					>A> NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					>A> ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	>A> 11571436	May 14, 2029	DP			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	>A> 11571436	May 14, 2029	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	>A> 11559637	Jul 21, 2039	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	>A> 11559637	Jul 21, 2039	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11541026	Feb 19, 2040	U-3356			
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	>A> 10533032	Jul 03, 2031	U-2214		>A> NCE	Jan 20, 2028
	>A> 10981942	Jun 13, 2031	DS DP			
	>A> 7838499	Jan 30, 2029	DS DP U-2214			
	>A> 8106021	Aug 22, 2028	U-2214			
	>A> 8802637	Aug 22, 2028	DS DP U-2214			
	>A> 8987323	May 14, 2032	DS DP			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					ODE-389	Dec 15, 2028
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11554102	Jan 11, 2033	DP			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040	DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	8143240	Jan 12, 2024	U-2942			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP U-724			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001				>A>	NP	Jun 23, 2024
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	>A> 10869869	Aug 30, 2033	U-3185		>A> I-894	Jun 22, 2025
	>A> 10869869*PED	Mar 02, 2034			>A> ODE-147	Jun 22, 2024
	>A> 7994185	Jan 20, 2030	DS DP U-1406		>A> ODE-182	Apr 30, 2025
	>A> 7994185	Jan 20, 2030	DS DP U-2031		>A> ODE-183	May 04, 2025
	>A> 7994185	Jan 20, 2030	DS DP U-2032		>A> PED	Dec 22, 2024
	>A> 7994185	Jan 20, 2030	DS DP U-2296		>A> PED	Oct 30, 2025
	>A> 7994185*PED	Jul 20, 2030			>A> PED	Nov 04, 2025
	>A> 8415345	Jan 20, 2030	DS DP U-1406		>A> PED	Dec 22, 2025
	>A> 8415345	Jan 20, 2030	DS DP U-2031			
	>A> 8415345	Jan 20, 2030	DS DP U-2032			
	>A> 8415345	Jan 20, 2030	DS DP U-2296			
	>A> 8415345*PED	Jul 20, 2030				
	>A> 8703781	Oct 15, 2030	DS DP U-1713			
	>A> 8703781	Oct 15, 2030	DS DP U-2032			
	>A> 8703781	Oct 15, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-2298			
	>A> 8703781*PED	Apr 15, 2031				
	>A> 8835443	Jun 10, 2025	U-2026			
	>A> 8835443	Jun 10, 2025	U-2027			
	>A> 8835443	Jun 10, 2025	U-2296			
	>A> 8835443	Jun 10, 2025	U-2298			
	>A> 8835443*PED	Dec 10, 2025				
	>A> 8952018	Oct 15, 2030	U-2027			
	>A> 8952018*PED	Apr 15, 2031				
	>A> 9233956	May 04, 2029	U-1811			
	>A> 9233956	May 04, 2029	U-2031			
	>A> 9233956	May 04, 2029	U-2032			
	>A> 9233956	May 04, 2029	U-2296			
	>A> 9233956*PED	Nov 04, 2029				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	>A> 10869869	Aug 30, 2033	U-3185		>A> I-894	Jun 22, 2025
	>A> 10869869*PED	Mar 02, 2034			>A> ODE-147	Jun 22, 2024
	>A> 7994185	Jan 20, 2030	DS DP U-1406		>A> ODE-182	Apr 30, 2025
	>A> 7994185	Jan 20, 2030	DS DP U-2031		>A> ODE-183	May 04, 2025
	>A> 7994185	Jan 20, 2030	DS DP U-2032		>A> PED	Dec 22, 2024
	>A> 7994185	Jan 20, 2030	DS DP U-2296		>A> PED	Oct 30, 2025
	>A> 7994185*PED	Jul 20, 2030			>A> PED	Nov 04, 2025
	>A> 8415345	Jan 20, 2030	DS DP U-1406		>A> PED	Dec 22, 2025
	>A> 8415345	Jan 20, 2030	DS DP U-2031			
	>A> 8415345	Jan 20, 2030	DS DP U-2032			
	>A> 8415345	Jan 20, 2030	DS DP U-2296			
	>A> 8415345*PED	Jul 20, 2030				
	>A> 8703781	Oct 15, 2030	DS DP U-1713			
	>A> 8703781	Oct 15, 2030	DS DP U-2032			
	>A> 8703781	Oct 15, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-2298			
	>A> 8703781*PED	Apr 15, 2031				
	>A> 8835443	Jun 10, 2025	U-2026			
	>A> 8835443	Jun 10, 2025	U-2027			
	>A> 8835443	Jun 10, 2025	U-2296			
	>A> 8835443	Jun 10, 2025	U-2298			
	>A> 8835443*PED	Dec 10, 2025				
	>A> 8952018	Oct 15, 2030	U-2027			
	>A> 8952018*PED	Apr 15, 2031				
	>A> 9233956	May 04, 2029	U-1811			
	>A> 9233956	May 04, 2029	U-2031			
	>A> 9233956	May 04, 2029	U-2032			
	>A> 9233956	May 04, 2029	U-2296			
	>A> 9233956*PED	Nov 04, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	May 23, 2028	U-3499			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 001	>A> 11117871	Mar 13, 2038	DS DP U-3535		>A> NCE	Feb 01, 2028
	>A> 8324208	Dec 11, 2028	DS DP			
	>A> 8557834	Jun 22, 2027	U-1238			
	>A> 8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 002	>A> 11117871	Mar 13, 2038	DS DP U-3535		>A> NCE	Feb 01, 2028
	>A> 8324208	Dec 11, 2028	DS DP			
	>A> 8557834	Jun 22, 2027	U-1238			
	>A> 8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 003	>A> 11117871	Mar 13, 2038	DS DP U-3535		>A> NCE	Feb 01, 2028
	>A> 8324208	Dec 11, 2028	DS DP			
	>A> 8557834	Jun 22, 2027	U-1238			
	>A> 8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 004	>A> 11117871	Mar 13, 2038	DS DP U-3535		>A> NCE	Feb 01, 2028
	>A> 8324208	Dec 11, 2028	DS DP			
	>A> 8557834	Jun 22, 2027	U-1238			
	>A> 8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROO</u>						
N 216951 005	>A> 11117871	Mar 13, 2038	DS DP U-3535		>A> NCE	Feb 01, 2028
	>A> 8324208	Dec 11, 2028	DS DP			
	>A> 8557834	Jun 22, 2027	U-1238			
	>A> 8815884	Jun 22, 2027	DP U-1238			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	>A> 11564917	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	>A> 11564917	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	>A> 11564917	Mar 07, 2036	U-1995			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11311488	Jun 10, 2041	DP U-1995			
	>A> 11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 005					NPP	Dec 16, 2025
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	>A> 11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	>A> 11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	>A> 11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	>A> 11559501	Jan 06, 2042	DP			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 215408 001					>A> CGT	Aug 16, 2023
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	>A> 10071066	Oct 10, 2034	U-3524		>A> NCE	Jan 27, 2028
	>A> 10745343	Jan 05, 2038	U-3523			
	>A> 8399520	Dec 25, 2023	DS DP U-3523			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	>A> 10071066	Oct 10, 2034	U-3524		>A> NCE	Jan 27, 2028
	>A> 10745343	Jan 05, 2038	U-3523			
	>A> 8399520	Dec 25, 2023	DS DP U-3523			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	11542239	Jul 23, 2039	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	>A> 11564916	Aug 13, 2029	U-3525			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	>A> 11564916	Aug 13, 2029	U-3525			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	>A> 11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	>A> 11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	>A> 11564886	Mar 07, 2032	DP U-3531			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3534			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3533			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 9949997	May 17, 2034	U-3532			
	>A> 9949997	May 17, 2034	U-3533			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	8501758	Aug 27, 2030	DS DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	>A> 11571398	May 16, 2040	U-3183			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	>A> 11173134	Sep 10, 2035	U-3257			
	>A> 11173134	Sep 10, 2035	U-3536			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	>A> 11173134	Sep 10, 2035	U-3257			
	>A> 11173134	Sep 10, 2035	U-3536			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001					ODE-393 PED	Mar 25, 2029 Sep 25, 2029
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 11357935	Sep 24, 2038	DP			
	>A> 11357935*PED	Mar 24, 2039				
	>A> 11439777	May 24, 2040	DP			
	>A> 11439777*PED	Nov 24, 2040				
	>A> 11464923	Jun 19, 2040	DP			
	>A> 11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 11357935	Sep 24, 2038	DP			
	>A> 11357935*PED	Mar 24, 2039				
	>A> 11439777	May 24, 2040	DP			
	>A> 11439777*PED	Nov 24, 2040				
	>A> 11464923	Jun 19, 2040	DP			
	>A> 11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 11357935	Sep 24, 2038	DP			
	>A> 11357935*PED	Mar 24, 2039				
	>A> 11439777	May 24, 2040	DP			
	>A> 11439777*PED	Nov 24, 2040				
	>A> 11464923	Jun 19, 2040	DP			
	>A> 11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	>A> 11357935	Sep 24, 2038	DP			
	>A> 11357935*PED	Mar 24, 2039				
	>A> 11439777	May 24, 2040	DP			
	>A> 11439777*PED	Nov 24, 2040				
	>A> 11464923	Jun 19, 2040	DP			
	>A> 11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 11554229	Feb 23, 2036	U-2133			
	8327844	Oct 24, 2023	U-2133			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					>A> M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	>A> 10456354	Oct 25, 2038	DP			
	>A> 11110054	Oct 25, 2038	DP			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001				ODE-109	Mar 04, 2023
					ODE-117	May 06, 2023
					>A> ODE-128	Jan 18, 2024
					>A> ODE-152	Aug 02, 2024
					>A> PED	Jul 18, 2024
					>A> PED	Feb 02, 2025
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	002				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	001				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	002				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	003				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	004				ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Jan 18, 2024
					ODE*	Aug 02, 2024
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	>A> 11564916	Aug 13, 2029	U-3530		
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	>A> 11564916	Aug 13, 2029	U-3528		
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002	>A> 11564916	Aug 13, 2029	U-3528		
<u>IVACAFTOR - KALYDECO</u>						
N 207925	003	>A> 11564916	Aug 13, 2029	U-3528		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	001	>A> 11564916	Aug 13, 2029	U-3527		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	002	>A> 11564916	Aug 13, 2029	U-3527		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	001	>A> 11564916	Aug 13, 2029	U-3529		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	002	>A> 11564916	Aug 13, 2029	U-3529		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	>A> 11564916	Aug 13, 2029	U-3526			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	>A> 11564916	Aug 13, 2029	U-3526			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	>A> 11564916	Aug 13, 2029	U-3526			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	10071985	Aug 17, 2037	DS DP			
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	10071985	Aug 17, 2037	DS DP			
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	>A> 11090386	Feb 23, 2036	U-3519			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	>A> 11090386	Feb 23, 2036	U-3519			
<u>LEVOKETONAZOLE - RECORLEV</u>						
N 214133 001					ODE-385	Dec 30, 2028
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 001	11541012	Mar 25, 2039	DP			
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 002	11541012	Mar 25, 2039	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	>A> 11571328	Sep 07, 2040	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	11534395	Jan 26, 2036	DP U-2764			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					ODE-388	Nov 23, 2028
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001					>A> ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002					>A> ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003					>A> ODE-398	Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004					>A> ODE-398	Apr 28, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001					ODE-392	Feb 17, 2029

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196	002				ODE-392	Feb 17, 2029
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196	003				ODE-392	Feb 17, 2029
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854	001	>A> 11571518	Jun 14, 2041	DP U-3515		
		>A> 11571518	Jun 14, 2041	DP U-3516		
		>A> 11571518	Jun 14, 2041	DP U-3517		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	>A> 11559523	Nov 18, 2030	DP U-3522		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734	002	11547758	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	003	11547758	Apr 18, 2027	U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734	004	11547758	Apr 18, 2027	U-1029		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	002	11517563	Apr 16, 2038	DP	Y	
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860	001	11511252	Sep 21, 2029	DP		
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814	001				NCE	Dec 01, 2027
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712	001				>A> ODE-397	Feb 28, 2029
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907	001				I-905 ODE-390	Dec 16, 2025 Nov 29, 2028
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159	001	7229630	Jul 31, 2023	DP		
		7575757	Jul 31, 2023	DP		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496	001				CGT	Jul 17, 2023
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059	001	>A> 10342780	Dec 16, 2036	DS DP		
		>A> 10464905	Dec 16, 2036	U-3518		
		>A> 10695323	Dec 16, 2036	DS DP U-3518		
		>A> 10918622	Dec 16, 2036	U-3518		
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059	002	>A> 10342780	Dec 16, 2036	DS DP		
		>A> 10464905	Dec 16, 2036	U-3518		
		>A> 10695323	Dec 16, 2036	DS DP U-3518		
		>A> 10918622	Dec 16, 2036	U-3518		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	002	11564912	Feb 26, 2029	U-3511		
		11564912	Feb 26, 2029	U-3512		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	>A> 11576903	Dec 30, 2040	DP			
	>A> 11576904	Aug 12, 2040	U-3537			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001 >A>	11534444	Oct 04, 2038	U-1943		>A> ODE-400	May 27, 2029
<u>RISPERIDONE - RYKINDO</u>						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	>A> 11571425	May 20, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					NPP	Dec 23, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005					NPP	Dec 23, 2025
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					>A> ODE-402	Jun 16, 2029
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					>A> M-287	Jan 31, 2026
<u>SIROLIMUS - FYARRO</u>						
N 213312 001					ODE-386	Nov 22, 2028
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001					ODE-391	Mar 22, 2029
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	>A> 11583542	Jul 27, 2040	DP			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001					ODE-384	Sep 20, 2029
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	>A> 11160779	Mar 19, 2040	U-3521			
	>A> 11560354	Mar 06, 2039	DP U-3520			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	>A> 11160779	Mar 19, 2040	U-3521			
	>A> 11560354	Mar 06, 2039	DP U-3520			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	>A> 11160779	Mar 19, 2040	U-3521			
	>A> 11560354	Mar 06, 2039	DP U-3520			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	>A> 10519146	May 21, 2038	DS DP			
	>A> 11236091	May 20, 2040	DS DP U-3306			
	>A> 11426404	Aug 11, 2040	U-3306			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	>A> 11566011	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	>A> 11566011	Feb 12, 2035	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	>A> 11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	>A> 11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	>A> 11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	>A> 11559530	Nov 28, 2037	U-1500			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	>A> 6821987	Apr 26, 2024	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	>A> 6821987	Apr 26, 2024	DS DP U-3100			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	>A> 10869869	Aug 30, 2033	U-3184		>A> I-895	Jun 22, 2025
	>A> 10869869*PED	Mar 02, 2034			>A> ODE-148	Jun 22, 2024
	>A> 7378423	May 29, 2027	DS DP		>A> ODE-182	Apr 30, 2025
	>A> 7378423*PED	Nov 29, 2027			>A> ODE-183	May 04, 2025
	>A> 8580304	Jan 28, 2032	DP		>A> PED	Dec 22, 2024
	>A> 8580304*PED	Jul 28, 2032			>A> PED	Oct 30, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-1712		>A> PED	Nov 04, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2020		>A> PED	Dec 22, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2037			
	>A> 8703781	Oct 15, 2030	DS DP U-2302			
	>A> 8703781	Oct 15, 2030	DS DP U-2305			
	>A> 8703781*PED	Apr 15, 2031				
	>A> 8835443	Jun 10, 2025	U-1581			
	>A> 8835443	Jun 10, 2025	U-1582			
	>A> 8835443	Jun 10, 2025	U-2020			
	>A> 8835443	Jun 10, 2025	U-2037			
	>A> 8835443	Jun 10, 2025	U-2302			
	>A> 8835443	Jun 10, 2025	U-2305			
	>A> 8835443*PED	Dec 10, 2025				
	>A> 8952018	Oct 15, 2030	U-2020			
	>A> 8952018*PED	Apr 15, 2031				
	>A> 9155706	Jan 28, 2032	DP			
	>A> 9155706*PED	Jul 28, 2032				
	>A> 9271941	Jan 28, 2032	DP			
	>A> 9271941*PED	Jul 28, 2032				
	>A> 9399021	Jan 28, 2032	DP			
	>A> 9399021*PED	Jul 28, 2032				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	>A> 10869869	Aug 30, 2033	U-3184		>A> I-895	Jun 22, 2025
	>A> 10869869*PED	Mar 02, 2034			>A> ODE-148	Jun 22, 2024
	>A> 7378423	May 29, 2027	DS DP		>A> ODE-182	Apr 30, 2025
	>A> 7378423*PED	Nov 29, 2027			>A> ODE-183	May 04, 2025
	>A> 8580304	Jan 28, 2032	DP		>A> PED	Dec 22, 2024
	>A> 8580304*PED	Jul 28, 2032			>A> PED	Oct 30, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-1712		>A> PED	Nov 04, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2020		>A> PED	Dec 22, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2037			
	>A> 8703781	Oct 15, 2030	DS DP U-2302			
	>A> 8703781	Oct 15, 2030	DS DP U-2305			
	>A> 8703781*PED	Apr 15, 2031				
	>A> 8835443	Jun 10, 2025	U-1581			
	>A> 8835443	Jun 10, 2025	U-1582			
	>A> 8835443	Jun 10, 2025	U-2020			
	>A> 8835443	Jun 10, 2025	U-2037			
	>A> 8835443	Jun 10, 2025	U-2302			
	>A> 8835443	Jun 10, 2025	U-2305			
	>A> 8835443*PED	Dec 10, 2025				
	>A> 8952018	Oct 15, 2030	U-2020			
	>A> 8952018*PED	Apr 15, 2031				
	>A> 9155706	Jan 28, 2032	DP			
	>A> 9155706*PED	Jul 28, 2032				
	>A> 9271941	Jan 28, 2032	DP			
	>A> 9271941*PED	Jul 28, 2032				
	>A> 9399021	Jan 28, 2032	DP			
	>A> 9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	>A> 10869869	Aug 30, 2033	U-3184		>A> I-895	Jun 22, 2025
	>A> 10869869*PED	Mar 02, 2034			>A> ODE-148	Jun 22, 2024
	>A> 7378423	May 29, 2027	DS DP		>A> ODE-182	Apr 30, 2025
	>A> 7378423*PED	Nov 29, 2027			>A> ODE-183	May 04, 2025
	>A> 8580304	Jan 28, 2032	DP		>A> PED	Dec 22, 2024
	>A> 8580304*PED	Jul 28, 2032			>A> PED	Oct 30, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-1712		>A> PED	Nov 04, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2020		>A> PED	Dec 22, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2037			
	>A> 8703781	Oct 15, 2030	DS DP U-2302			
	>A> 8703781	Oct 15, 2030	DS DP U-2305			
	>A> 8703781*PED	Apr 15, 2031				
	>A> 8835443	Jun 10, 2025	U-1581			
	>A> 8835443	Jun 10, 2025	U-1582			
	>A> 8835443	Jun 10, 2025	U-2020			
	>A> 8835443	Jun 10, 2025	U-2037			
	>A> 8835443	Jun 10, 2025	U-2302			
	>A> 8835443	Jun 10, 2025	U-2305			
	>A> 8835443*PED	Dec 10, 2025				
	>A> 8952018	Oct 15, 2030	U-2020			
	>A> 8952018*PED	Apr 15, 2031				
	>A> 9155706	Jan 28, 2032	DP			
	>A> 9155706*PED	Jul 28, 2032				
	>A> 9271941	Jan 28, 2032	DP			
	>A> 9271941*PED	Jul 28, 2032				
	>A> 9399021	Jan 28, 2032	DP			
	>A> 9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	>A> 10869869	Aug 30, 2033	U-3184		>A> I-895	Jun 22, 2025
	>A> 10869869*PED	Mar 02, 2034			>A> ODE-148	Jun 22, 2024
	>A> 7378423	May 29, 2027	DS DP		>A> ODE-182	Apr 30, 2025
	>A> 7378423*PED	Nov 29, 2027			>A> ODE-183	May 04, 2025
	>A> 8580304	Jan 28, 2032	DP		>A> PED	Dec 22, 2024
	>A> 8580304*PED	Jul 28, 2032			>A> PED	Oct 30, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-1712		>A> PED	Nov 04, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2020		>A> PED	Dec 22, 2025
	>A> 8703781	Oct 15, 2030	DS DP U-2037			
	>A> 8703781	Oct 15, 2030	DS DP U-2302			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	>A> 8703781	Oct 15, 2030	DS DP U-2305			
	>A> 8703781*PED	Apr 15, 2031				
	>A> 8835443	Jun 10, 2025			U-1581	
	>A> 8835443	Jun 10, 2025			U-1582	
	>A> 8835443	Jun 10, 2025			U-2020	
	>A> 8835443	Jun 10, 2025			U-2037	
	>A> 8835443	Jun 10, 2025			U-2302	
	>A> 8835443	Jun 10, 2025			U-2305	
	>A> 8835443*PED	Dec 10, 2025				
	>A> 8952018	Oct 15, 2030			U-2020	
	>A> 8952018*PED	Apr 15, 2031				
	>A> 9155706	Jan 28, 2032	DP			
	>A> 9155706*PED	Jul 28, 2032				
	>A> 9271941	Jan 28, 2032	DP			
	>A> 9271941*PED	Jul 28, 2032				
	>A> 9399021	Jan 28, 2032	DP			
	>A> 9399021*PED	Jul 28, 2032				
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001					>A> ODE-401	Apr 28, 2029
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		>A> I-906	Jan 19, 2026
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		>A> I-906	Jan 19, 2026
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371			
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003					ODE-387	Nov 19, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE-394	Dec 17, 2028
<u>XENON XE-129 HYPERPOLARIZED - XENOVIEW</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		>A> I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145			
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
>A>	11591340	Aug 15, 2037	U-1745			
>A>	11591340	Aug 15, 2037	U-2145			
>A>	11591340	Aug 15, 2037	U-2537			
>A>	11591340	Aug 15, 2037	U-2666			
>A>	11591340	Aug 15, 2037	U-3063			
>A>	11591340	Aug 15, 2037	U-3486			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZINC SULFATE MONOHYDRATE - ZINC SULFATE</u>						
A 216145 001					>A> CGT	Aug 14, 2023

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43<sup>rd</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)